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ABSTRACT  
The possibility of obtaining material for foetal molecular analysis without the need 
of invasive procedures has been a long wished improvement of practice in prenatal 
diagnostics. The demonstration of the presence of foetal cells and circulating foetal 
free-DNA in a sample of mother-to-be’s blood promised that a non-invasive 
approach for prenatal diagnostics is near to becoming a reality. 
The presence of foetal cells (albeit in low numbers) in maternal blood has been 
known since 1893, when Schomorl [1] described throphoblast cells in lung 
circulation of pregnant women who deceased from eclampsia. However, following 
the first observation numerous attempts to isolate these cells have proven 
disappointing. The main reasons for the lack of success with fetal cells isolation can 
be attributed to the very tiny proportion of fetal cells in the total maternal blood cell 
population. Moreover, isolation of fetal cells failed to demonstrate the origin of 
these cells using genetic profiling.  
The presence of cell-free foetal circulating DNA sequences in the plasma of 
pregnant women was first described in 1997, when the Lo group [2] reported the 
presence of Y chromosome DNA sequences in pregnant circulation.  
The demonstration of foetal genetic material in maternal circulation incited a new 
era of non-invasive prenatal diagnostics based on free foetal DNA, with the purpose 
of replacing the invasive approaches based on villi sampling, cordonocentesis and 
amniocentesis. Obtaining chorionic villi, amniocentesis or cord blood specimens is 
expensive and requires an invasive procedure that carries a small risk to the foetus 
and the possibility of adverse maternal effects, such as unnerving risk of 
miscarriage. Moreover, these tests are not provided until late in the first trimester 
thus implying a rate – limiting step in the provision of prenatal diagnosis: only 
pregnant women at the highest risk of having a foetus with a genetic syndrome or 
another disorder of major clinical significance have been eligible to these tests.  
In this study we considered that genetic prenatal diagnosis could have forensic 
applications, in particular in cases of rape resulting in pregnancy. So, we explored 
the opportunity and ethical issues related to the introduction of non-invasive 
prenatal testing for non-medical applications, such as sex determination and 
 6 
paternity testing. In particular, based on our laboratory analyses we achieved proof 
of principle of a non-invasive test for forensic purposes.  
We obtain approval for our studies from the Ethics Committee of the University - 
Hospital of Padova (Protocol n. 2105 P / 2010), Italy. First of all we demonstrated 
the applicability of cell free DNA in human identification. Then, we enrolled 
pregnant women and their partner and investigated the STR profiles obtained from 
free DNA and nucleated red blood cells in peripheral blood of pregnant women that 
were compared to profiles of the putative father, in order to define paternity. The 
STR profiles in free DNA were investigated using consolidated methods, by 
performing multiplex PCR and sequencing, without succesfull results that we 
attributed to the low sensitivity of the method. This result pushed us to investigate 
the applicability of new high throughput technologies (e.g. next generation 
sequencing) in plasma DNA of mother’s-to be. This new approach, of potential 
interest for forensic genetics, seems to be promizing thank to its high sensitivity. 
The best results with profiling fetal DNA from maternal blood specimens were 
obtained from DNA profiling of nucleated red blood cells of embryonic origin when 
enrichment by Fluorescent Activated Cell Sorting (FACS) was performed. For 
enrichment a combination of monoclonal antibodies was employed: all amplified 
alleles amplified from sorted cells, others than those of the mother, matched the 
alleles of the putative father. 
Our study, which is the first one to investigate DNA profiling analysis on nucleated 
fetal red blood cells for forensic genetics, demonstrated that non-invasive prenatal 
paternity testing could be developed as a tool for the identification of perpetrators of 
rape in case of resulting pregnancy. More efforts need to be spend to optimize the 
isolation of fetal cells. The proof of principle that non invasive prenatal paternity 
testing on DNA of rare fetal cells circulating in pregnant blood is feasible justifies 
further efforts in developing this new approach.  
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RIASSUNTO 
La possibilità di ottenere materiale genetico di origine fetale per diagnosi prenatale 
senza l’ausilio di procedure invasive è sempre stato considerato un interesse 
condiviso in campo ostetrico ginecologico. Da quando è stata dimostrata la presenza 
di cellule fetali e di DNA plasmatico entrambi di origine fetale nel circolo periferico 
delle donne in gravidanza questa opportunità ha iniziato ad essere indagata al fine di 
poter essere proposta nella pratica clinica. 
Che cellule fetali siano presenti, anche se in numero molto esiguo, nel circolo 
periferico delle donne gravide è noto fin dal 1893, quando il patologo tedesco 
Schomorl ha descritto la presenza di trofoblasti nel circolo polmonare di 14 donne 
decedute per eclampsia [1], ma i tentativi di isolamento sono sempre risultati 
fallimentari. I principali motivi del mancato successo sono da ricercare nella 
esiguità di questa quota cellulare e nella mancanza di dimostrazione dell’origine 
fetale attraverso tecniche di profiling genetico della stessa. 
Nel 1997 il gruppo di Yo [2] ha dismostrato la presenza di frammenti di DNA libero 
di origine fetale nel sangue periferico delle donne gravide, attraverso 
l’amplificazione di sequenze del cromosoma Y nel plasma di queste donne.  
Così, dalla dimostrazione della presenza di materiale genetico di origine fetale nel 
circolo materno è iniziata una nuova era della diagnosi prenatale non invasiva, 
particolarmente incentrata sulla frazione di acidi nucleici liberi. Infatti, il recupero 
dei villi e/o del liquido amniotico sono gravati da costi sostenuti e dai rischi legati 
all’invasività del prelievo sia per il prodotto del concepimento che per la donna, con 
un seppur basso ma esistente rischio di perdita della gravidanza stessa. 
Inoltre, questi approcci invasivi sono eseguiti non prima del termine del primo 
trimestre di gravidanza o nel secondo: essi sono proposti solo alle donne con già 
rilevato rischio di sindromi genetiche malformative o con rischio aumentato in 
funzione dell’età materna. 
Nel nostro studio abbiamo considerato che la diagnosi prenatale può avere anche 
applicazioni forensi, in particolare nei casi di gravidanza esitata dopo stupro. 
Abbiamo così analizzato l’opportunità e la valenza etica di introdurre tecniche di 
diagnosi prenatale non invasiva per scopi non squisitamente clinici, come la 
determinazione del sesso e della paternità. 
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Abbiamo ottenuto l’approvazione del Comitato Etico dell’Azienda Ospedaliero 
Universitaria di Padova (Protocollo n. 2105 P / 2010), attraverso la preliminare 
proposta di considerazioni bioetiche sullo studio.  
Abbiamo, dunque, iniziato il nostro studio attraverso la dimostrazione 
dell’applicabilità della frazione libera del DNA, cosiddetto DNA plasmatico o DNA 
libero circolante, ai fini dell’identificazione personale in soggetti sani, comprese 
donne non gravide. Quindi, abbiamo arruolato donne in gravidanza afferenti al 
Servizio di Gestione della Gravidanza della Divisione Ostetrica dell’Azienda 
Ospedaliera di Padova e i loro partner in funzione di investigare i profili genetici 
degli short tandem repeats (STR) usati in genetica forense ai fini di identificazione 
personale, ottenuti dalla frazione di DNA libero e dagli eritroblasti fetali entrambi 
circolanti nel sangue periferico delle donne e di confrontarli con il profilo dei 
partner al fine di definirne e dimostrarne la paternità. 
Nella frazione libera di DNA i consolidati metodi di amplificazione del DNA non 
hanno permesso di dimostrare la presenza di profilo aggiuntivo rispetto a quello 
materno. Questo ci ha spinto ad indagare l’applicabilità delle più recenti tecnologie 
come il sequenziamento di ultima generazione, cosiddetto pyrosequenzing, nel 
plasma delle future mamme. Questo approccio, di nuovo interesse nella disciplina 
della genetica forense, ci ha permesso di rilevare la presenza di sequenze fetali nel 
plasma materno. 
Migliori risultati li abbiamo ottenuti isolando gli eritroblasti di origine fatale 
attraverso arricchimento con tecniche di sorting cellulare (Fluorescent Activated 
Cell Sorting, FACS), con una combinazione di anticorpi monoclonali: tutti gli alleli 
amplificati diversi da quelli materni sono risultati essere coerenti con quelli del 
partner, ovvero del “presunto” padre, poi confermati alla nascita con quelli del 
bambino. 
Il nostro studio, che rappresenta la prima apllicazione dell’impiego degli eritroblasti 
fetali in genetica forense, dimostra che la diagnosi di paternità non invasiva può 
rapprentare un valido mezzo nell’identificazione della figura dello stupratore in caso 
di successiva gravidanza. Altri studi dovranno comunque essere eseguiti al fine di 
ottimizzare l’isolamento delle cellule fetali. 
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ABBREVIATIONS 
 
CD: cluster differentiation 
CE: capillary electrophoresis 
cfDNA: cell free DNA 
CVS: chorionic villi sampling 
EBV: Epstein-Barr virus  
emPCR: emulsion polymerase chain reaction  
FACS: Fluorescence Activated Cell Sorting 
FIVET: fertilization in vitro embryo transfer  
EDTA: ethylenediamine tetra-acetic acid  
ffDNA: free foetal DNA 
F: newborn 
FISH: in situ fluorescent hybridization  
GS: Genome Sequencer  
GWs: gestation weeks 
LOH: loss of heterozygosity 
M: mother 
MACS: Magnetic Activated Cell Sorter  
MID: multiplex identifier 
NIPD: non-invasive prenatal diagnosis 
NIPPT: non-invasive prenatal paternity testing  
NRBC: nucleated red blood cells 
P: presumptive biological father 
PPi: pyrophosphate  
US: ultra sound 
SNPs: single nucleotide polymorphisms 
STRs: short tandem repeats 
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INTRODUCTION 
 
1. Invasive and non-invasive prenatal genetic diagnostics  
 
Prenatal genetic diagnostics is a collection of procedures to assess the presence of 
abnormalities in the foetus. 
Prenatal diagnosis can be achieved through either invasive methods or non-invasive 
methods. Invasive approaches consist in chorionic villi sampling (CVS), 
cordocentesis and amniocentesis. The major non-invasive methods include ultra 
sound (US), doppler, Tri-test and neck translucency. Although these are extremely 
useful in monitoring the pregnancy, they are entirely inappropriate for the diagnosis 
of many diseases of genetic origin (both chromosomal and monogenic), for which 
the only possibility of diagnosis consists in invasive sampling and molecular 
procedures. 
Invasive prenatal diagnosis by amniocentesis and CVS started to be used in the late 
60's and in the 80’s respectively. Over the decades, these techniques have been 
extremely refined thanks to gynecologists’s abilities and as a result of significant 
technological advances, thus minimizing the risk of miscarriage after withdrawal. 
Unfortunately, the risk of miscarriage has not been completely cleared and is 
currently estimated at around 0.5-1%. For this reason, and because of high costs, 
only a small group of women is eligible to invasive prenatal diagnosis. In particular, 
women older than 35 years, since at this age the risk of having a child with 
chromosomal abnormalities increases dramatically, and the latter risk is quite 
comparable to the risk of a miscarriage risk related to the invasive procedures. 
Although the advanced maternal age is indicative of an increased risk of general 
chromosomal disorder, even women under the age of 35 may have affected 
children. However, in this risk group the costs and the risk invasive prenatal genetic 
testing do not counter balance the small risk of giving birth of a child with a 
chromosomal abnormality.  
If it were possible to obtain foetal material to conduct genetic research without 
invading the uterus in any way, prenatal genetic diagnosis could be offered to all 
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pregnant women, regardless of their risk of having an affected child. For this reason 
interest in the development of techniques for a non-invasive prenatal genetic 
diagnosis is high. 
These techniques are based on recovery of foetal genetic material from maternal 
blood, both in the form of foetal cells and in the form of free foetal nucleic acids. 
 
 
2. Foetal cells in maternal blood 
 
The discovery of the presence of foetal cells in the maternal circulation dates back 
to 1893 when the German pathologist Schmorl described the presence of 
trophoblast cells in the lung circulation of 14 pregnant women who died because of 
eclampsia [1] Later, in 1957 erythrocytes of foetal origin were isolated from the 
maternal circulation [2] and ten years later, thanks to the identification of 
metaphases with an XY karyotype, foetal leukocytes were detected in the peripheral 
blood of a pregnant women carrying a male foetus [3]. In particular, such finding 
delivered the first demonstration that trophoblast cells are not the only foetal 
cellular component found in maternal blood; however, the existence of foetal cells 
in maternal circulation remained controversial for many years.  
Only the introduction of more sensitive analytical techniques, such as in situ 
fluorescent hybridization (FISH) and DNA amplification by PCR irrefutably 
demonstrated the presence of foetal cells in the maternal circulation. 
Even if it is now widely recognized that foetal cells are present in maternal blood, 
data relating to foetal cell frequency are often discordant. Lack of concordance 
regarding the frequencies of foetal cells have been attributed to the difficulties of 
isolating these cells related to both their scarcity and fragility. It is very likely that 
cells are lost during the various steps of the isolation process, which is difficult to 
standardize. 
Through the use of FISH, Krabchi and colleagues have reported the presence of 
about 2-6 foetal cells per milliliter of maternal blood [4]. These numbers are 
comparable to those obtained through quantitative real time PCR assays, which is 
around 1-4 foetal cells per milliliter of maternal blood [5]. However many authors 
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failed to confirm these data, isolating lower numbers of cells or even isolating no 
cell at all [6 - 8]. 
Numerous studies have shown an increase in number of foetal cells in the maternal 
circulation during complications of pregnancy, such as diabetes and preeclampsia [9 
- 11] and in cases of foetuses with aneuploidy, suggesting the use of foetal cells in 
pregnancy monitoring.  
In particular, Bianchi and colleagues demonstrated an increase in the number of 
foetal cells in blood of pregnant women carrying a foetus with Down syndrome 
[12]. Also other aneuploidies, including those affecting the sex chromosomes, have 
been shown to be characterized by an increase of foetal cells in maternal circulation 
[13].  
Presence of relatively high numbers of foetal cells in the circulation of a pregnant 
woman can be explained by a defective placentation, as found in the presence of 
preeclampsia and aneuploidy, resulting in a altered placental barrier, with 
consequent increase in the transfer of foetal cells to the maternal circulation [14]. 
Other factors influencing the concentration of foetal cells in maternal blood were 
found to be related to foetal gestational age [15], multiple pregnancies, foetal 
maternal blood group incompatibility and the previous use of invasive procedures to 
the uterus [16].  
Numerous approaches have been evaluated to isolate and analyze foetal cells. They 
include centrifugation on a density gradient, the use of immunomagnetic beads, 
antibody conjugation, single cell micromanipulation, Fluorescence Activated Cell 
Sorting (FACS) and Magnetic Activated Cell Sorting (MACS). FACS and MACS 
are mainly based on the recognition of foetal cells through antigen-antibody 
complexing, wherein antibodies to surface markers of the foetal cells are 
respectively conjugated to fluorochromes or magnetic microbeads. FACS sorting is 
also based on using physical parameters of the foetal cell such as specific volume 
and size.  
Based on the use of antibodies, the success of FACS and MACS for recognizing 
foetal cells depends on the specificity of the antibody. The most commonly used 
antibody is the anti CD71, which recognizes the transferrin surface membrane 
receptor expressed on almost all nucleated foetal blood cells in the first trimester 
[17]. Its expression decreases with gestational age but increases in foetuses with 
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chromosomal aneuploidy. It is also expressed on the surface of a subpopulation of 
maternal cells, constituting its main disadvantage. Other antibodies used are the anti 
CD36 antibody (against the receptor thrombospondin), anti glycophorin A, antigens 
against blood group I / i and antibodies FB3-2, 2-6B / 6 and H3-3: none of these 
antibodies in itself represents the optimal antibody capable of isolation of foetal 
cells. Antibodies against the embryonic and foetal globin are also employed. The ς-
globin and the ε-globin, although embryo specific markers, are expressed only for a 
short gestational period. The ς-globin decreases drastically from the sixth to seventh 
week of gestation and the ε-globin from the twelfth week is present only in half of 
the nucleated blood cells of the embryo [18]. With regard to foetal globin, the γ-
globin has the advantage of being produced by foetal erythrocytes for an extended 
period of pregnancy, even if its use results in a greater contamination by maternal 
cells [19].  
So, up to day, except for the embryonic globin, no specific antigen for the foetal 
cells has yet been found, so it remains difficult to isolate foetal cells without 
maternal contamination.  
The more frequently adopted strategy to isolate foetal cells is the use of a 
combination of more than one of the above reported procedures. The problem of the 
rarity of foetal cells could be overcome by culturing of the foetal cells to obtain a 
sufficient number of cells for genetic analysis. 
Also in vitro expansion of trophoblast cells and foetal leukocytes has been proposed 
[20 - 21], albeit without satisfactory results.  
Three main types of foetal cells that have been isolated in the maternal circulation 
are: trophoblast cells, leukocytes and erythroblasts. 
The cell type of choice should have three requirements: 
- be predominant in the maternal circulation during the first trimester of pregnancy; 
- have a limited half-life in maternal blood; 
- possess morphological characteristics distinguishable from the maternal blood 
cells. 
Trophoblast cells have a morphology which allows unequivocal identification under 
the microscope. They are released into the maternal blood during the first trimester 
of pregnancy; however, trophoblast cells are not easily isolated in normal 
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pregnancies because they are quickly captured from pulmunary circulation [22]. 
Moreover, they present more than one nucleus, limiting their usefulness for 
cytogenetic diagnosis.  
Leukocytes are the first type of foetal cells isolated with success from maternal 
blood by Herzenberg and co-workers [23] performing a fluorescence separation 
based on the maternal and foetal HLA antigens differences: this approach is not 
universally applicated, because it needs information on the paternal HLA antigens 
and thus assumes known paternity. Further, even if leukocytes have the potential to 
proliferate in vitro, their use for genetic testing is not recommended because they 
may persist in the maternal circulation up to 27 years after delivery [24]. This 
microchimerism might cause a diagnostic error, as there is a risk that selected 
leukocytes do not belong to the current pregnancy. 
Foetal erythroblasts or nucleated red blood cells (NRBCs) are cells with a single 
nucleus and are relatively well differentiated. They also have a short life-span 
compared to foetal lymphocytes given their limited proliferative capacity [25], 
making it unlikely that they persist throughout pregnancy, thus eliminating the risk 
of microchimerisms. These characteristics make NRBCs particularly suitable for 
non-invasive prenatal diagnostic testing. 
In 1957, Kleihauer et al. demonstrated the presence of erythroblasts circulating in 
maternal blood [26]. In 1964, Clayton et al. observed NRBCs more frequently under 
rhesus incompatibility or following amniocentesis and pregnancy termination [27]. 
NRBCs are one of the first hematopoietic cells produced during foetal development 
and these cells are abundantly present in the foetal circulation during the early 
developmental period [28]. At the interface between foetal and maternal tissues 
transfer of erythrocytes including NRBCs into the maternal circulation 
predominates over that of other cell types including leukocytes and trophoblasts.  
In 1990, Bianchi et al. described how to enrich NRBCs by FACS using a 
monoclonal antibody against the transferrin receptor (CD71), which is highly 
expressed on erythoblasts [29]. Other investigators confirmed these observations 
using a variety of monoclonal antibodies and cell enrichment techniques [30 - 31]. 
These successful results demonstrate the potential of using NRBCs for non-invasive 
prenatal diagnosis. 
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However, the isolation of foetal cells from the maternal circulation presents 
considerable challenges, given their limited numbers. Foetal cells are estimated to 
range from 1 to 5000 cells in maternal blood [32]. Hamada et al. used FISH on 
mononuclear cells isolated by density gradient separation from maternal blood to 
identify Y chromosome-bearing cells: they screened as many as 144,000 nuclei to 
find one single foetal cell containing DNA that hybridized to the Y chromosome 
probe [33]. 
An increased frequency of foetal cells with gestational age was observed. Bianchi et 
al. examined the number of foetal-cell DNA equivalents present in maternal blood 
by PCR amplification of a Y chromosome-specific sequence and found 
approximately one foetal cell per 1 mL of maternal blood [34]. 
Thus, although the presence of foetal NRBCs in maternal blood is well established, 
and NRBCs are considered the best target for non-invasive prenatal diagnosis, their 
detection remains problematic. Moreover, undoubtedly, some NRBCs are of 
maternal origin [35]. De Graff et al. used foetal hemoglobin to differentiate 
maternal from foetal NRBCs, but 20% of all foetal hemoglobin positive NRBCs 
were still of maternal origin [36]. These results imply that the origin of each cell 
needs to be confirmed for reliable clinical use when performing non-invasive 
prenatal diagnosis through analysis of cells recovered from maternal blood.  
In vitro expansion of foetal cells could help to solve this issue. If selective induction 
of proliferation occurs in vitro, foetal genetic material could be amplified. Lo et al. 
were the first to culture foetal erythroid progenitors from the peripheral blood of 
pregnant women [37]. However, these results have not been consistently validated 
in other laboratories, and thus far selective amplification of foetal over maternal 
hemopoietic progenitors has not been successful [38]. 
Foetal mesenchymal stem cells have also been identified in maternal blood [39]: 
they appear early, starting from the seventh gestation week (GW), with 
characteristic morphology and immunophenotype. Unfortunately, however, the 
attempts to isolate the latter cells have shown that also these cells are extremely 
rare, excluding the possibility of their use in non-invasive prenatal diagnosis [40]. 
 
Although by now numerous cases of non-invasive prenatal diagnosis have been 
reported using various types of foetal cells in relatively small population of 
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pregnant women, no results of studies on larger series have been published that 
justify the optimism of smaller studies. 
Concerning foetal cells persistence in maternal circulation, all observations to date 
suggest their persistence in maternal blood. The latter would imply that this 
approach could theoretically lead to misdiagnosis in cases of pluriparity. 
 
 
3. Cell free foetal DNA 
 
3.1 Cell free DNA 
Cell-free DNA (cfDNA) is defined as DNA occurring in the extracellular 
compartment. 
In 1948, Mandel and Metais discovered the presence of circulating nucleic acids in 
plasma and serum [41]. Studies on circulating cell free DNA or plasma DNA, were 
at first focused on autoimmune diseases [42]. Thirty years after the cfDNA 
discovery, Leon et al. demonstrated elevated cfDNA levels in cancer patients when 
compared with healthy subjects [43]. Milestones on cfDNA are highlighted in Table 
1.  
 
YEAR EVENT 
1948  Discovery of cfDNA in blood [44] 
1965  Oncogenesis and cfDNA [45]  
1966- 1973 Detection of high levels in patients with rheumatoid arthritis, systemic lupus erythematosus, 
leukemia, and other diseases [46 - 49] 
1972- 1975 Procedures of determining cfDNA in normal plasma samples [50] 
1977 Evidence of increased levels of cfDNA in cancer patients depending on tumor stage and treatment 
[51] 
1989 Characteristics of cfDNA and tumor DNA in cancer patients [52]  
1994-1999 Tumor-related genetic alterations in circulating DNA [53 - 59] 
1997 Foetal DNA in plasma of pregnant women [60] 
1998 Description of plasma DNA chimerism after transplantation [61] 
2000-2010 Circulating DNA in diagnosis and prognosis of numerous diseases (tumors, trauma, heart infarction, 
stroke etc.) [62 - 68] 
2010 Oncogenic transformation of cultured cells by circulating DNA in plasma [69]. 
 
Table 1: Milestones in the research of cfDNA 
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3.1.1 Cell free DNA in cancer 
Cancer-derived oncogenic mutations in plasma DNA has been demonstrated only in 
1994, when Vasioukhin and co-workers investigated point mutations of N-RAS in 
cfDNA of patients affected by myelodysplastic syndrome or acute myelogenous 
leukemia [70]. 
Being loss of heterozygosity (LOH) a common observation in tumor cells, the 
phenomena was also investigated in cfDNa of tumor patients. The LOH was found 
in the plasma of cancer patients, contributing to evidence of tumor derived DNA in 
the circulation. LOH patterns have been associated with particular cancer types such 
as breast [71], lung [72], kidney cancer [73], and melanoma [74]. In particular, 
serum LOH detection has been considered to be a good marker in predicting 
severity, disease outcome and therapeutic response in melanoma and breast cancer 
[75], suggesting the possibility of early stage cancer screening by LOH detection in 
plasma [76]. 
As a result of these findings, the interest of many researchers is directed to search 
for other sequence specific fragments of cfDNA in plasma and serum. 
One of the areas of rapid progress is the detection of viral DNA in the plasma of 
patients suffering from virus-associated tumors. An intimate relationship of 
circulating Epstein-Barr virus (EBV) DNA has been shown with nasopharyngeal 
carcinoma [77], lymphomas [78] and gastric cancer [79]. 
Also human papilloma-virus (HPV) DNA in patients suffering from cervical cancer 
has been investigated [80], showing that detection of HPV DNA in plasma is 
associated with disease recurrence and distant metastasis.  
 
3.1.2 Cell free DNA in organ transplants 
The discovery of tumor-derived plasma DNA prompted researchers to search for 
donor-derived DNA in plasma of transplant recipients. In plasma of recipients donor 
derived DNA has been successfully identified in cases of kidney [81], liver and 
bone marrow transplantations [82]. However, it is still unclear whether this kind of 
“plasma DNA chimerism” has any direct biological role in enhancing graft 
acceptance, such as been suggested for “cellular chimerism”.  
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3.1.3 Cell free foetal DNA 
Recognizing the pseudo-malignant nature of the placenta, Lo et al. searched for and 
were able to identify the presence of foetal DNA in the plasma of pregnant women 
in 1997 [83]. These researchers discovered the existence of free foetal DNA 
(ffDNA) in maternal plasma detecting Y chromosome specific DNA sequences in 
women bearing male foetuses: Y-specific sequences were detected in 80% and 70% 
of samples of plasma and serum respectively of women with a male foetus. 
These same researchers have also demonstrated bidirectional traffic of foetal cells at 
the foetal - maternal interface during pregnancy [84]. These evidences suggested 
that maternal blood might be a useful source of material for non-invasive prenatal 
diagnosis [85]. The vast majority of free-DNA in maternal plasma is of maternal 
origin (maternal free DNA, mfDNA), accounting for around 95% of total free-DNA 
in plasma [85]. This aspect considerably reduces the efficacy and specificity of 
conventional or real time allele-specific PCR approaches for the detection of foetal 
loci.  
However, recently it has been shown that ffDNA molecules in maternal plasma are 
smaller than mfDNA [86], offering possibilities for enrichment of foetal DNA that 
should improve the detection of foetal loci.  
The mechanism of foetal DNA release has not yet been elucidated. One possibility 
is that foetal DNA is released from dying cell, but the identity of the cell types 
predominantly involved in such DNA release is not definitely resolved: in 
anembryonic pregnancies Alberry et al. reported a trophoblastic origin [87]. 
The heated debate on the origin of foetal DNA in maternal circulation is ongoing. 
The hypothesis that achieved most consensus suggested a placental origin, due to 
massive apoptosis of syncytiotrophoblasts constantly being replaced on the surface 
of the placenta [88]. There are three evidences in favour of this hypotesis: 
1. absence of ffDNA in placental mosaicism [89]; 
2. presence of ffDNA after childbirth with placenta retention [90]; 
3. detection of foetal sequences with specific methylation patterns of the 
placenta [91]. 
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It was also suggested that ffDNA originated from apoptotic foetal cells in maternal 
circulation. Although theoretically possible, the scarcity of foetal cells does not 
correspond to the amounts of ffDNA reported.  
Finally, one might hypothesize a direct transfer of DNA from the embryo-foetal 
compartment to the maternal circulation. The latter hypothesis found support from 
findings of ffDNA in the amniotic liquid samples [92]. 
Concerning clearance, plasma foetal DNA has a more rapid clearance kinetics 
compared to that of foetal nucleated cells; further more, although most of the cells 
are cleared within weeks from the maternal circulation, it has been shown that sub 
populations persist for up to after delivery [93]. Foetal DNA is cleared rapidly from 
maternal plasma, with a half-life of minutes [94]. The notable differences between 
foetal cell- and free- DNA clearance suggest that the predominant cell populations 
involved in these two phenomena may be distinct. It has been suggested that the 
trophoblasts may be the predominant cell population involved in the liberation of 
foetal DNA into the cell-free fraction. Foetal erythroblasts, on the other hand, have 
been postulated to be the predominant foetal cell population found in maternal 
blood [95]. 
Concerning the amount, total cell free DNA is not constant: it varies considerably 
both in the circulation of healthy individuals and in that of healthy pregnant women. 
More over it varies throughout pregnancy. Although there might be a tendency of 
greater fluctuations to occur around 25 weeks of gestation (2.4- to 4.5-fold) 
compared to other moments during gestation, there is no clear increase in variation 
toward the end of pregnancy [96].  
 
 
4. State of the art of non-invasive prenatal paternity testing througt STRs 
analysis 
To our knowledge no laboratory is currently performing a complete paternity testing 
from maternal blood according to accuracy, precision and reproducibility of results 
as required in forensic DNA testing.  
By analyzing free foetal DNA from maternal plasma the only locus that reliably 
amplified with AmpFLSTR Identifiler kit (Applied Biosystems®) is amelogenin, 
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which revealed only foetal gender, while the amplification of other autosomal loci is 
only sporadic and is not sufficient for reliable paternity testing. More success is 
obtained with AmpFLSTR Yfiler kit (Applied Biosystems®), which, in case of 
male foetuses, successfully amplifies between 6 and 16 Y foetal loci [97].  
Vecchione et al. employed simultaneously 10 X-STR loci and the amelogenin gene 
in the same multiplex QF PCR [98] on free foetal DNA of maternal plasma: a mean 
of 2.67 ± 1.28 X-STR markers per sample (range 1-5) of paternally inherited foetal 
alleles was detected in pregnant women carrying a female foetus.  
Concerning the foetal cells in maternal plasma [99] isolation of foetal DNA is 
reliable in non-pathological condition from nucleated erythrocytes whereas until 
now no paternity testing has been performed on foetal cells circulating in maternal 
blood.  
 24 
References 
[1] Schmorl G. Pathologisch-anatomische untersuchungen ueber Publereklapmsie. 
1893 Vogel, Leipzig  
[2] Kleihauer E, Braun H, Betke K. Demonstration von foetalem hämoglobin in den 
erythrocyten eines blutausstrichs. Klein. Wochenschr 1957;15: 637 
[3] Walknowska J, Conte FA, Grumback MM. Pratical and implications of 
foetal/maternal lymphocyte transfer. Lancet 1969;1:1119-22 
[4] Krabchi K, Gros-Louis F, Yan J, Bronsard M, Masse J, Forest JC, Drouin R. 
Quantification of all foetal nucleated cells in maternal blood between the 18th and 
22nd weeks of pregnancy using molecular cytogenetic techniques. Clin Genet. 
2001;60: 145-50 
[5] Ariga H, Ohto H, Busch MP, Imamura S, Watson R, Reed W, Lee TH. Kinetics 
of foetal cellular and cell-free DNA in the maternal circulation during and after 
pregnancy: implications for noninvasive prenatal diagnosis. Transfusion 2001;41: 
1524-30 
[6] Gänshirt Ahlert D, Burschyk M, Garritsen HSP. Magnetic cell sorting and tha 
transferrin receptor as potential means of prenatal diagnosis from maternal blood. 
Am J Obstet Gynecol 1992;166: 1350-55. 
[7] Durrant L, McDowall K, Holmes R, Liu D. Non-invasive prenatal diagnosis by 
isolation of both trophoblasts and foetal nucleated red blood cells from the 
peripheral blood of pregnant women. Br J Obstet Gynaecol. 1996;103: 219-22 
[8] Mavrou A, Kouvidi E, Antsaklis A, Souka A, Kitsiou Tzeli S, Kolialexi A. 
Identification of nucleated red blood cells in maternal circulation: A second step in 
screening for foetal aneuploidies and pregnancy complications. Prenat Diagn. 
2007;27: 150-3 
[9] Bianchi DW. Prenatal diagnosis by analysis of foetal cells inmaternal blood. J 
Pediatr. 1995;127: 847-56 
[10] Holzgreve W, Ghezzi F, DiNaro E, Ganshirt D, Maymon E, Hahn S. Feto-
maternal cell traffic is disturbed in preeclampsia. Obstetrics and Gynecology 
1998;91: 669–72 
[11] Troeger C, Holzgreve W, Ladewig A, Zhong XY, Hahn S. Examination of 
maternal plasma erythropoietin and activin A concentrations with regard to 
 25 
circulatory erythroblast levels in normal and preeclamptic pregnancies. Foetal 
Diagn Ther. 2006; 21: 156-60 
[12] Bianchi DW, Simpson JL, Jackson LG, Elias S, Holzgreve W, Evans MI, 
Dukes KA, Sullivan LM, Klinger KW, Bischoff FZ, Hahn S, Johnson KL, Lewis D, 
Wapner RJ, de la Cruz F. Foetal gender and aneuploidy detection using foetal cells 
in maternal blood: analysis of NIFTY I data. National Institute of Child Health and 
Development Foetal Cell Isolation Study. Prenat Diagn. 2002;22: 609-15 
[13] Krabchi K, Gadji M, Forest JC, Drouin R. (2006) Quantification of all foetal 
nucleated cells in maternal blood in different cases of aneuploidies. Clin Genet. 69: 
145-54 
[14] Al-Mufti R, Hambley H, Albaiges G, Lees C, Nicolaides KH. Increased foetal 
erythroblasts in women who subsequently develop pre-eclampsia. Hum Reprod. 
2000;15: 1624-8 
[15] Guetta E, Simchen MJ, Mammon-Daviko K, Gordon D, Aviram-Goldring A, 
Rauchbach N, Barkai G. Analysis of foetal blood cells in the maternal circulation: 
challenges, ongoing efforts, and potential solutions. Stem Cells Dev. 2004;13: 93-9 
[16] Jansen, MW, Brandenburg H, Wildschut HI, Martens AC, Hagenaars AM, 
Wladimoroff JW, in’t Veld PA. The effect of chorionic villus sampling on the 
number of foetal cells isolated from maternal blood and on maternal serum 
alphafetoprotein levels. Prenat Diagn 1997;17: 953–9 
[17] Zheng YL, Zhen DK, De Maria M, Berry SM, Wapner RJ, Evans MI, 
Copeland D, Williams JM, Bianchi DW. Search for the optimal foetal cell antibody: 
results of immunophenotyping studies using flow cytometry. Hum Genet. 1997;100: 
35-42 
[18] Mesker WE, Ouwerkerk-Van Velzen MCM, Oosterwijk JC, Bernini LF, 
Golbus MS, Kanhai HHH, Van Ommen GJB, Tanke HJ. Two-color 
immunocytochemical staining of gamma (g) and epsilon (var-epsilon) type 
hemoglobin in foetal red cells. Prenat Diagn. 1998;18: 1131–37 
[19] Zheng YL, De Maria M, Zhen DK, Vadnais TJ, Bianchi DW. Flow sorting of 
foetal erythroblast using intracytoplasmic antifoetal haemoglobin: preliminary 
observations on matrnal samples. Prenat Diagn 1995;15: 897-99 
 26 
[20] Eridani S, Mazza U, Massaro P, La Targia ML, Maiolo AT, Mosca A. 
Cytokine effect on ex vivo expansion of haemopoietic stem cells from different 
human sources. Biotherapy 1998;11: 291-6 
[21] Jansen MW, Korver-Hakkennes K, van Leenen D, Brandenburg H, Wildschut 
HI, Wladimiroff JW, Ploemacher RE. How useful is the in vitro expansion of foetal 
CD34+ progenitor cells from maternal blood samples for diagnostic purposes? 
Prenat Diagn 2000;20: 725-31 
[22] Sargent IL, Johansen M, Chau S, Redma CWG. Clinical experience: isolating 
trophoblasts from maternal blood. Annals of the New York Academy of Sciences 
1994;731: 154–61 
[23] Herzenberg LA, Bianchi DW, Schröder J, Cann HM, Iverson GM. Foetal cells 
in the blood of pregnant women: detection and enrichment by fluorescent activated 
cell sorting. Proc Natl Acad Sci USA 1979;76: 1453-1455 
[24] Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, De Maria M. Male foetal 
progenitor cells persist in maternal blood for as long as 27 years post-partum. Proc 
Natl Acad Sci USA 1996;93: 705-8 
[25] Pearson HA. Life-span of the foetal red blood cell. J Pediatr 1967;70:166–71 
[26] Kleihauer E, Braun H, Betke K. Demonstration of foetal hemoglobin in 
erythrocytes of a blood smear. Klin Wochenschr 1957;35:637–8] 
[27] Clayton EM Jr, Feldhaus WD, Whitacre FE. Foetal erythrocytes in the 
maternal circulation of pregnant women. Obstet Gynecol 1964;23:915–9 
[28] Ganshirt D, Garritsen H, Miny P, Holzgreve W. Foetal cells in maternal 
circulation throughout gestation. Lancet 1994;343:1038–9 
[29] Bianchi DW, Flint AF, Pizzimenti MF, Knoll JH, Latt SA. Isolation of foetal 
DNA from nucleated erythrocytes in maternal blood. Proc Natl Acad Sci USA 
1990;87:3279–83 
[30] Price JO, Elias S, Wachtel SS, et al. Prenatal diagnosis with foetal cells 
isolated from maternal blood by multiparameter flow cytometry. Am J Obstet 
Gynecol 1991;165:1731–7 
[31] Wachtel S, Elias S, Price J, et al. Foetal cells in the maternal circulation: 
isolation by multiparameter flow cytometry and confirmation by polymerase chain 
reaction. Hum Reprod 1991;6:1466–9 
 27 
[32] Ganshirt-Ahlert D, Pohlschmidt M, Gal A, Miny P, Horst J, Holzgreve W. 
Ratio of foetal to maternal DNA is less than 1 in 5000 at different gestational ages 
in maternal blood. Clin Genet 1990;38:38–43 
[33] Hamada H, Arinami T, Kubo T, Hamaguchi H, Iwasaki H. Foetal nucleated 
cells in maternal peripheral blood: frequency and relationship to gestational age. 
Hum Genet 1993;91: 427–32 
[34] Bianchi DW, Williams JM, Sullivan LM, Hanson FW, Klinger KW, Shuber 
AP. PCR quantitation of foetal cells in maternal blood in normal and aneuploid 
pregnancies. Am J Hum Genet 1997;61:822–9 
[35] Slunga-Tallberg A, el-Rifai W, Keinanen M, et al. Maternal origin of 
transferrin receptor positive cells in venous blood of pregnant women. Clin Genet 
1996;49:196–9 
[36] de Graaf IM, Jakobs ME, Leschot NJ, Ravkin I, Goldbard S, Hoovers JM. 
Enrichment, identification and analysis of foetal cells from maternal blood: 
evaluation of a prenatal diagnosis system. Prenat Diagn 1999;19:648–52 
[37] Lo YM, Morey AL, Wainscoat JS, Fleming KA. Culture of foetal erythroid 
cells from maternal peripheral blood. Lancet 1994;344:264–5 
[38] Bohmer RM, Johnson KL, Bianchi DW. Foetal and maternal progenitor cells in 
co-culture respond equally to erythropoietin. Prenat Diagn 2001;21:818–23 
[39] Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM. 
Identification of mesenchymal stem/progenitor cells in human first-trimester foetal 
blood, liver, and bone marrow. Blood. 2001;98: 2396-402 
[40] O'Donoghue K, Choolani M, Chan J, de la Fuente J, Kumar S, Campagnoli C, 
Bennett PR, Roberts IA, Fisk NM. Identification of foetal mesenchymal stem cells 
in maternal blood: implications for non-invasive prenatal diagnosis. 2003;Mol Hum 
Reprod. 9: 497-502 
[41] Mandel P, Métais P. Les acides nucléiques du plasma sanguin chez l’homme. 
C. R. Acad. Sci. Paris 1948;142: 241-3 
[42] Leon SA, Ehrlich GE, Shapiro B, Labbate VA. Free DNA in the serum of 
rheumatoid arthritis patients. J Rheumatol 1977; 4: 139-43 
[43] Leon S, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer 
patients and the effect of therapy. Cancer Res 1977; 37: 646-50 
 28 
[44] Mandel P, Metais P. Les acides nucleiques du plasma sanguin chez l'homme. C 
R Seances Soc Biol Fil 1948;142:241–3 
[45] Bendich A, Wilczok T, Borenfreund E. Circulating DNA as a possible factor in 
oncogenesis. Science 1965;148:374–6 
[46] Tan EM, Schur PH, Carr RI, Kunkel HG. Deoxyribonucleic acid (DNA) and 
antibodies to DNA in the serum of patients with systemic lupus erythematosus. J 
Clin Invest 1966;45:1732–40 
[47] Kofler D, Agnello V, Winchester R, Kunkel HG. The occurrence of single-
stranded DNA in the serum of patients with systemic lupus erythematosus and other 
diseases. J Clin Invest 1973;52:198–204 
[48] Perlin E, Moquin RB. Serum DNA levels in patients with malignant disease. 
Am J Clin Pathol 1972;58:601–2 
[49] Steinman CR. Free DNA in serum and plasma from normal adults. J Clin 
Invest 1975;56:512–5 
[50] Kamm RC, Smith AG. Nucleic acid concentrations in normal human plasma. 
Clin Chem 1972;18:519–22 
[51] Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of 
cancer patients and the effect of therapy. Cancer Res 1977;37:646–50 
[52] Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic 
characteristics of the DNA found in the plasma of cancer patients. Oncology 
1989;46:318–22 
[53] Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. 
Pointmutations of the N-ras gene in the blood plasma DNA of patients with 
myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol 
1994;86:774–9 
[54] Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble 
normal and mutated DNA sequences from single-copy genes in human blood. 
Cancer Epidemiol Biomark Prev 1994;3:67–71 
[55] Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite 
alterations in serum DNA of head and neck cancer patients. Nat Med 1996;2:1035–
7 
 29 
[56] Chen XQ, Stroun M, Magnenat JL, et al. Microsatellite alterations in plasma 
DNA of small cell lung cancer patients. Nat Med 1996;2:1033–5 
[57] Anker P, Lefort F, Vasioukhin V, et al. K-ras mutations are found in DNA 
extracted from the plasma of patients with colorectal cancer. Gastroenterology 
1997;112:1114–20 
[58] Chiang PW, Beer DG, Wei WL, Orringer MB, Kurnit DM. Detection of erbB-
2 amplifications in tumors and sera from esophageal carcinoma patients. Clin 
Cancer Res 1999;5:1381–6 
[59] Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman 
JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in 
serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67–70 
[60] Lo YM, Corbetta N, Chamberlain PF, et al. Presence of foetal DNA in 
maternal plasma and serum. Lancet 1997;350:485–7 
[61] Lo YM, TeinMS, Pang CC, Yeung CK, Tong KL, HjelmNM. Presence of 
donor-specific DNA in plasma of kidney and liver-transplant recipients. Lancet 
1998;351:1329–30 
[62] Rainer TH, Wong LK, Lam W, et al. Prognostic use of circulating plasma 
nucleic acid concentrations in patients with acute stroke. Clin Chem 2003;49:562–9 
[63] Chang CP, Chia RH, Wu TL, Tsao KC, Sun CF, Wu JT. Elevated cell-free 
serum DNA detected in patients with myocardial infarction. Clin Chim Acta 
2003;327:95–101 
[64] Hu L, Chen G, Yu H, Qiu X. Clinicopathological signi!cance of RASSF1A 
reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int 
2010;4:423–32 
[65] Cabral RE, Caldeira-de-Araujo A, Cabral-Neto JB, Costa Carvalho MD. 
Analysis of GSTM1 and GSTT1 polymorphisms in circulating plasma DNA of lung 
cancer patients. Mol Cell Biochem 2010;338:263–9 
[66] Arnalich F, Menendez M, Lagos V, et al. Prognostic value of cell-free plasma 
DNA in patients with cardiac arrest outside the hospital: an observational cohort 
study. Crit Care 2010;14:R47 
 30 
[67] Liggett T, Melnikov A, Yi QL, et al. Differential methylation of cell-free 
circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. 
Cancer 2010;116:1674–80 
[68] Kamat AA, Baldwin M, Urbauer D, et al. Plasma cell-free DNA in ovarian 
cancer: an independent prognostic biomarker. Cancer 2010;116:1918–25 
[69] Garcia-Olmo DC, Dominguez C, Garcia-Arranz M, et al. Cell-free nucleic 
acids circulating in the plasma of colorectal cancer patients induce the oncogenic 
transformation of susceptible cultured cells. Cancer Res 2010;70:560–7 
[70] Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. Point 
mutations of the N-ras gene in the blood plasma DNA of patients with 
myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol. 1994 
Apr;86(4):774-9 
[71] Silva JM, Dominguez G, Garcia JM, Gonzalez R, Villanueva MJ, Navarro F, 
Provencio M, San Martin S, España P, Bonilla F. Presence of tumor DNA in plasma 
of breast cancer patients: clinicopathological correlations. Cancer Res. 1999 Jul 
1;59(13):3251-6 
[72] Sozzi G, Musso K, Ratcliffe C, Goldstraw P, Pierotti MA, Pastorino U. 
Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer 
patients: a prospect for early diagnosis. Clin Cancer Res. 1999 Oct;5(10):2689-92 
[73] Goessl C, Heicappell R, Münker R, Anker P, Stroun M, Krause H, Müller M, 
Miller K. Cancer Res. Microsatellite analysis of plasma DNA from patients with 
clear cell renal carcinoma. 1998 Oct 15;58(20):4728-32 
[74] Fujiwara Y, Chi DD, Wang H, Keleman P, Morton DL, Turner R, Hoon DS. 
Plasma DNA microsatellites as tumor-specific markers and indicators of tumor 
progression in melanoma patients. Cancer Res. 1999 Apr 1;59(7):1567-71 
[75] Stroun M, Anker P, Lyautey J, Lederrey C, Maurice PA. Isolation and 
characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin 
Oncol 1987;23:707–12 
[76] Schwarzenbach H, Müller V, Stahmann N, Pantel K. Detection and 
characterization of circulating microsatellite-DNA in blood of patients with breast 
cancer. Ann N Y Acad Sci. 2004;1022:25-32 
 31 
[77] Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, 
Johnson PJ, Huang DP. Quantitative analysis of cell-free Epstein-Barr virus DNA in 
plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999 Mar 
15;59(6):1188-91 
[78] Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. Quantitative analysis of 
circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-
associated lymphoid malignancies. Br J Haematol. 2000 Oct; 111(1):239-46 
[79] Lo YM, Chan WY, Ng EK, Chan LY, Lai PB, Tam JS, Chung SC. Circulating 
Epstein-Barr virus DNA in the serum of patients with gastric carcinoma. Clin 
Cancer Res. 2001 Jul;7(7):1856-9 
[80] Widschwendter A, Blassnig A, Wiedemair A, Müller-Holzner E, Müller HM, 
Marth C. Human papillomavirus DNA in sera of cervical cancer patients as tumor 
marker. Cancer Lett. 2003 Dec 30;202(2):231-9 
[81] Lo YM, Tein MS, Pang CC, Yeung CK, Tong KL, Hjelm NM. Presence of 
donor-specific DNA in plasma of kidney and liver-transplant recipients. Lancet. 
1998 May 2;351(9112):1329-30 
[82] Lui YY, Chik KW, Chiu RW, Ho CY, Lam CW, Lo YM. Predominant 
hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched 
bone marrow transplantation. Clin Chem. 2002 Mar;48(3):421-7 
[83] Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, 
Wainscoat JS. Lancet. Presence of foetal DNA in maternal plasma and serum.1997 
Aug 16;350(9076):485-7 
[84] Lo YM, Lo ESF, Watson N, Noakes L, Sargent Il, Thilaganthan B, Wainscot Js 
Two-Way Cell Traffic Between Mother And foetus: Biologic And Clinical 
Implications. Blood 1996; 88:4390– 5 
[85] Lo YM, Tein MSC, Lau TK, Haines CJ, Leung TN, Poon PMK, Et Al. 
Quantitative Analysis Of Foetal Dna In Maternal Plasma And Serum: Implications 
For Noninvasive Prenatal Diagnosis. Am J Hum Genet 1998; 62:768–75 
[86] Chan KC, Zhang J, Hui AB, Wong N et Al. Size distributions of maternal and 
foetal DNA in maternal plasma. Clin. Chem. 2004; 50, 88–92 
 32 
[87] Alberry M, Maddocks D, Jones M, Abdel Hadi M, Abdel-Fattah S, Avent N, 
Soothill PW. Free foetal DNA in maternal plasma in anembryonic pregnancies: 
confirmation that the origin is the trophoblast. Prenat Diagn 2007; 27: 415–8 
[88] Hahn S, Ruppertz B, Holzgreve W. Foetal cells and cell free foetal nucleic 
acids in maternal blood: new tools to study abnormal placentation? Placenta. 2005; 
26: 515-26 
[89] Flori E, Doray B, Gautier E, Kohler M, Ernault P, Flori J, Costa JM. 
Circulating cell-free foetal DNA in maternal serum appears to originate from cyto- 
and syncytio-trophoblastic cells. Case report. Hum Reprod. 2004;19: 723-4 
[90] Jimbo M, Sekizawa A, Sugito Y, Matsuoka R, Ichizuka K, Saito H, Okai T. 
Placenta increta: Postpartum monitoring of plasma cell-free foetal DNA. Clin 
Chem. 2003; 49: 1540-1 
[91] Chan KC, Ding C, Gerovassili A, Yeung SW, Chiu RW, Leung TN, Lau TK, 
Chim SS, Chung GT, Nicolaides KH, Lo YM. Hypermethylated RASSF1A in 
maternal plasma: A universal foetal DNA marker that improves the reliability of 
noninvasive prenatal diagnosis. Clin Chem. 2006;52: 2211-8 
[92] Bianchi DW, LeShane ES, Cowan JM. Large amounts of cell-free foetal DNA 
are present in amniotic fluid. Clin Chem. 2001;47: 1867-9 
[93] Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, Demaria MA. Male Foetal 
Progenitor Cells Persist In Maternal Blood For As Long As 27 Years Postpartum. 
Proc Natl Acad Sci U S A 1996; 93:705–8 
[94] Lo YM, Zhang J, Leung TN, Lau TK, Chang A, Hjelm NM. Rapid Clearance 
of foetal DNA from maternal plasma. Am J Hum Genet 1999;64:218–24 
[95] Bianchi DW. Foetal Cells In The Maternal Circulation: Feasibility For Prenatal 
Diagnosis. Review. Br J Haematol 1999; 105:574–83 
[96] Zhong X Y, Bu¨ Rk M R., Troeger C, Kang A, Holzgreve W, Hahn S. 
Fluctuation of maternal and foetal free extracellular circulatory DNA in maternal 
plasma. Obstetrics & Gynecology 2000; 96: 991-6 
[97] Wagner J, Dzijan S, Marjanović D, Lauc G. Non-invasive prenatal paternity 
testing from maternal blood. Int J Legal Med. 2009;123(1):75-9 
[98] Vecchione G, Tomaiuolo M, Sarno M, Colaizzo D, Petraroli R, Matteo M, 
Greco P, Grandone E, Margaglione M. Foetal sex identification in maternal plasma 
 33 
by means of short tandem repeats on chromosome X. Ann N Y Acad Sci. 2008 
Aug;1137:148-56 
[99] Ganshirt D, Garritsen H, Miny P, HolzgreveW. Foetal cells in maternal 
circulation throughout gestation. Lancet 1994;343(8904):1038-9 
 34 
 
 
 35 
 
AIMS OF THE RESEARCH PROJECT 
 
The purpose of this study is to investigate non medical apllications of non invasive 
prenatal diagnosis and in particular to detective the paternally inherited 
polymorphism STRs, in a non-invasive approach, using free foetal DNA and rare 
foetal cells from maternal blood at different gestational ages to perform a non-
invasive prenatal paternity testing.  
Kinship and parental testing are usually performed by forensic laboratories using 
commercial kits for STR multiplex analysis. In these tests DNA is extracted from 
oral swabs or blood samples, but also banked pathological tissues are used for this 
purpose.  
Now a day, for prenatal paternity testing, in particular in case of rape resulting in 
pregnancy, the analysis could be performed on amniotic fluid or chorionic villi: 
such samples can be obtained only after the 13th gestational week (GW) and 
sampling is characterized by invasiveness, with a small but existing risk for both 
pregnant women and foetuses, as well as stressful for the women, with evident 
drawbacks. For these reasons the invasive approaches are not acceptable in non-
medical purposes such as prenatal paternity testing for forensic aims. 
A convenient non-invasive prenatal diagnostic approach has long been sought.  
A preliminary ethical evaluation has been performed and proposed. 
Our interest in ffDNA and NRBC analysis arises from the consideration that they 
could offer the possibility to perform non-invasive prenatal paternity testing, a 
usefull tool in forensic medicine in cases of rape resulting pregnancies. 
We proposed a preliminary ethical evaluation. 
Our interest in ffDNA and NRBC analysis arises from the consideration that they 
could offer the possibility to perform non-invasive prenatal paternity testing, a 
usefull tool in forensic medicine in cases of rape-related pregnancies. 
As first approach we considered the opportunity of perform DNA typing in 
circulating cell free nucleic acids in healthy subjects, in order to propose the use of  
cfDNA as a tool for forensic analysis. 
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Then, after approval by the Ethics Committee of the University – Hospital of 
Padova (No. 2105P) we enrolled a series of couples expecting a baby, with the aim 
to verify whether foetal polymorphic STR loci covered by NGM™ kit can also be 
successfully amplified from maternal blood and used for paternity testing. 
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Abstract 
Non-invasive prenatal diagnosis (NIPD) is becoming increasingly important and its 
application in prenatal diagnosis is reaching consensus in the scientific research 
community. We discuss the opportunities and ethics of non-invasive prenatal testing 
for non-medical purposes, including forensic genetics. A number of ethical issues 
arise from non-medical applications of NIPD, such as sex determination and 
paternity testing in earlier gestational age and subsequent offspring selection. NIPD 
provides a source of information about the genetic make-up of the foetus, avoiding 
the small but significant risk of pregnancy loss related to invasive testing such as 
amniocentesis or chorionic villi sampling. NIPD is characterized by: safety, early 
detection and easy sampling. These features of NIPD increase the opportunity of 
prenatal testing also for non-medical reasons. Even if NIPD can be qualified as a 
good practice prenatal diagnosis tout court remains a topic of ethical judgements. 
The non-medical use of NIPD will benefit from an informed and open debate 
involving both pregnant women and physicians. 
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Introduction 
The lack of risk of NIPD both for pregnant women and foetuses enhances the 
opportunity to use this technology for non-medical applications. The most evident 
non-medical issues addressed by NIPD are sex determination and paternity testing 
concerning potential pregnancy termination and illegal abortion [1]. 
 
Invasive – non-invasive access to foetal material 
The invasiveness of foetal sampling through amniocentesis or chorionic villi 
sampling (CVS) carries a small but significant risk of pregnancy loss. CVS and 
amniocentesis cause miscarriage in around 0.3–2% of cases with a slightly higher 
risk for CVS [2–5]. Even if wide consensus supports the application of CVS and 
amniocentesis for prenatal diagnosis of important diseases a convenient non-
invasive prenatal diagnostic approach that could eliminate the risk of pregnancy loss 
has longbeen sought. During pregnancy, the placental membranes separate the 
foetal and maternal circulations. However, a number of evidences points toward the 
incompleteness of this barrier for cellular [6] and free foetal DNA (ffDNA) 
trafficking [7]. Detection of ffDNA in samples of pregnant woman can be exploit 
for NIPD. 
 
Medical use of NIPD through ff-DNA 
To date NIPD through ffDNA is used for a number of clinical applications 
involving both the foetus and the pregnant woman, including for the foetus sex 
determination, single gene disorder detection and detection of aneuploidy and for 
the pregnant woman detection of elevated concentrations of ffDNA predictive for 
preeclampsia, hyperemesis gravidarum and pre-term delivery or other pregnancy-
related disorders such as Rhesus incompatibility. 
 
Non-medical use of NIPD: state of the art 
The two major non-clinical applications of NIPD are sex determination and 
paternity testing. Foetal gender determination was the first studied application of 
NIPD [8, 9]. Several Y chromosome specific sequences have been investigated for 
sex determination using real-time polymerase chain reaction (PCR) [10 – 12] in 
 40 
particular the SRY gene [13, 14] and the multicopy DYS14 sequence located within 
the TSPY [15]. Female foetuses have been directly identified through detection of 
paternally inherited X chromosome specific short tandem repeats (STRs) in 
pregnant blood [16]. 
Concerning prenatal paternity testing for forensic purposes, to our knowledge no 
groups are currently performing complete paternity testing on maternal plasma 
according to guidelines as required in forensic DNA testing. 
The only locus that reliably amplified with AmpFLSTR Identifiler kit (Applied 
Biosystems) is Amelogenin revealing only foetal gender, whereas the amplification 
of the autosomal loci is only sporadically found. More success is obtained with 
AmpFLSTR Yfiler kit (Applied Biosystems), which, in case of male foetuses, 
successfully amplifies between 6 and 16 foetal loci [17]. 
 
NIPD in general 
Generally speaking NIPD offers opportunities with specific ethical qualities. Firstly, 
safety that makes NIPD a more suitable approach also for women in non-risk 
pregnancies; secondly early detection which means longer time for parent decision-
making about the progress of pregnancy. Last but not least NIPD is characterized by 
easy sampling using a simple blood drawing: this in itself favourable feature 
introduces the risk of a poorly informed choice by the pregnant woman, resulting in 
a lack of true consent. All these features together (safety; early detection and easy 
sampling) ease of access of non-invasive prenatal testing also for non-medical 
reasons. 
 
Sex selection 
Sex determination is the more suitable application of cff DNA: it can be clinically 
relevant in cases of sex-linked diseases of the foetus, but it can also be used for non-
clinical motivated sex selection. 
In the last years questions are arising within the ethical debate regarding to use of 
these new reproductive technologies for selecting the sex of one’s child before 
implantation [18]. According to Italian law (L. 40/2004) the selection of embryos 
on the basis of sex is not permitted, but for the interruption of a pregnancy after 
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embryo transfer – in case of in vitro fertilization – (before the 90th day according to 
Italian law L. 194/1978) it is permitted for personal maternal reasons, and could 
include sex selection. The latter choice needs to be valued as a reproductive 
autonomy of the pregnant woman. 
The main concern is the selection of male foetuses following to the preference in 
some societies of giving birth to a boy over a girl such as in China [19] and in India 
[20]: this discrimination of women constitutes an injustice that should be prevented 
[21]. Moreover, large-scale execution of male selection could undermine a public 
good reinforcing a bias in the ratio between men and women [22]. 
 
Prenatal paternity testing 
Although to date non-invasive prenatal paternity testing (NIPPT) is not yet 
performed with accuracy and reliability required in forensic kinship parentage 
testing improvement of technologies are expected to make quality-certified NIPPT 
available in the near future. 
We can identify three major non-medical applications of NIPPT including: 
surveying the perpetrator in pregnancy as the result of a rape, unsure paternity in 
case of women with multiple partners, unsure paternity in case of suspect of 
erroneous embryo transfer. 
In the first case, paternity testing is neither questioned nor disputed. It serves 
forensic requirements and allows interruption of pregnancy if required by the 
pregnant woman, even if this might raise religious objections. 
Concerning ambiguous paternity in case of women with multiple partners some 
additional considerations need to be made. Refusing to perform paternity testing in 
these cases is clearly moralistic and unprofessional: such inference in the life of 
women reflects an illicit sentence of licentious life, which is not the assignment of a 
physician. The denial of access to NIPPT could have other ethically non-acceptable 
implications for the woman involved. A pregnant woman in case of ambiguous 
paternity could decide to terminate the pregnancy anyhow, or on the other hand 
decide to continue pregnancy with remaining uncertainty about the kinship. Another 
questionable implication of this position favours the expansion of services or 
laboratories that provide NIPPT without legal, deontological or ethical guarantees. 
Paternity testing typically postnatal paternity testing is performed by private or and 
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academic laboratories, after direct contact with the applicants. Even if also paternal 
consent in postnatal paternity testing is required a number of laboratories offer via 
the wwweb paternity testing without any guarantee regarding consent and privacy 
[23]. This practice is likely to extend to prenatal paternity testing in a near future. A 
long this line NIPPT will become available through the wwweb and with the risk of 
lesion of privacy and consent rights with consequent denial of autonomy and 
responsibility of involved subjects. 
For these reasons we retain that empirical research into pregnant women’s attitudes, 
needs and preferences are necessary for the debate and decision-making process. 
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Abstract 
Circulating cell free nucleic acids have been detected in peripheral blood specimens 
of healthy subjects as well as in patients. In recent years applications that analyze 
circulating cell free DNA (ccfDNA) have increased in particular for non-invasive 
diagnosis such as early tumor detection and non-invasive prenatal diagnosis. 
With the aim to test the applicability of ccfDNA analysis in human identification, 
we verified short tandem repeats (STRs) PCR amplification in extracellular 
circulating DNA. We report complete concordance between amplified alleles from 
the cell free fractions and the matched DNA samples from whole blood, 
demonstrating that ccfDNA can be exploited for identification purposes.  
In forensic sciences cell free blood samples are not used for human profiling. Here 
we propose that plasma can be considered a useful matrix in cases, such as 
unambiguous sample tracking in diagnostic routine, in the coming age of non 
invasive genetic prenatal diagnosis or in contested cases of toxicological analysis.  
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Introduction 
Studies of circulating nucleic acids promise exciting developments in molecular 
diagnostics in the years to come. 
Literature reported only two attempts investigating human identification through 
plasma DNA: a case report investigating three short tandem repeats (STRs) without 
validation for forensic purposes [1] and a more recent study [2] that however did not 
report results on plasma samples, even if plasma samples were mentioned in the 
introduction and material and methods paragraphs. 
So, until now, to our knowledge no data have been published of successful studies 
that investigated human identification using an established panel of polymorphic 
STR loci starting from samples of cell free plasma that were also validated on 
matched cellular samples.  
We embarked on a study aiming to determine whether extracellular DNA (i.e. cell 
free DNA, cfDNA) present in plasma can be used to support human genetic 
identification by STR analysis.  
 
 
Materials and methods 
1. Ethics 
The study was approved by the ethics committee of the University - Hospital, 
Padova, Italy (No. 2105P). Consent was obtained from all subjects. The study 
protocol was conform the guidelines of the “World Medical Association Declaration 
of Helsinki—Ethical Principles for Medical Research Involving Human Subjects” 
adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, as 
revised in Tokyo, Japan, 2004. 
 
2. Samples collection  
A flexible 18 G or 20 G, 11⁄4 Teflon catheter (Angiocath, Becton Dickinson, UT) 
was inserted in a superficial arm vein to obtain 2 ml of venous blood in EDTA from 
10 men and 10 non-pregnant women (all healthly volunteers). Specimens were 
numbered for anonymous work-up. Age ranged from 26 to 33 years and women 
included in the study disclosed no previous pregnancies. 
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1 ml of whole blood was centrifuged at 4°C for 10 min 1000 g (Heraeus Fresco 21 
Centrifuge, Thermo Electron Corporation, Karlsruhe, DE) within 1 hours from the 
blood drawing. The clear supernatant obtained after centrifugation was transferred 
to a new 2,5 ml micro tube, re-centrifuged at 4°C for 15 minutes at 2,000x g to 
eliminate platelets in the plasma sample. There after all cells were removed and 
approximately 600ul of plasma was obtained. Three 15ul aliquots of each plasma 
sample were microscopically inspected and absence of cells was confirmed. 
TE buffer (10 mM Tris, 0,1 mM EDTA, pH 8,0) was used as blank of extraction 
every 5th samples. 
 
3. DNA preparation and quantification  
ccfDNA was extracted in two replicates from 200 ul of plasma and in four negative 
controls (TE buffer) using a QIAamp Mini blood kit (Quiagen, Valencia, CA) 
according to the manufacturer’s protocol DNA purification from blood or body 
fluids (Spin protocol). The final elution volume was 100 ul. The eluted DNA were 
combined, obtaining 200 ul of eluted DNA for each subject. CcfDNA obtained was 
stored at -20°C until further use. 
DNA Quantification was performed by real-time PCR (RT-PCR) using the relative 
quantification with a standard curve method. Albumin (gene) was used as reference 
(FW 5’ TGAAACATACGTTCCCAAAGAGTTT ‘3, RW 5’ 
CTCTTCTCAGAAAGTGTGCATAT ‘3 probe FAM-TAMRA 5’ 
TGCTGAAACATTCACCTTCCATGCAC ‘3). The Albumin amplicon sequence 
measured 78 bp and was monitored on an ABI7900 sequence detection system 
using SDS Software v 1.2..  
As profile control, 100 ul of DNA from 200 ul for each whole blood sample was 
obtained with the same extraction protocol.  
 
4. DNA profiling 
Genetic human identification analysis was performed by simultaneous PCR 
amplification of fifteen DNA STR autosomal loci and a sex determination marker, 
amelogenin, using the commercial kit AmpFl STR NGM (AB). Autosomal STR 
loci (D3S1358, vWA, D16S539, D2S1338, D8S1179, D21S11, D18S51, D19S433, 
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TH01, FGA, D10S1248, D22S1045, D2S441, D1S1656 & D12S391) and the 
specific sex STR locus were amplified from the extracted ccfDNA and DNA: the 
29-cycle amplification was executed according to the original manufacturer’s 
protocol in a 25ul final reaction volume, consisting of 10 ul SGM plus reaction mix, 
5ul NGM primer set and 10ul of ccfDNA at concentrations ranging from 0,08 to 0,1 
ng/ul as measured by RT-PCR or 10ul of DNA at 0.1ng/ul concentration.  
The positive controls were represented by the human Control DNA 007 (0,1 ng/ul) 
provided by the manufacturer’s kit AmpFl STR NGM. The negative controls were 
represented by the TE Buffer samples previously extracted.  
All amplifications were performed on DNA thermal cyclers GeneAmp PCR System 
9700 (AB).  
Amplified fragments were resolved on a ABI Prism 310 Genetic Analyzer (AB) and 
genotyping was carried out using GenemapperID v3.2 software (AB).  
Electrophoresis was run using a 50 cm capillary and POP-4 polymer (AB) by 
mixing 1,5 ul of the PCR product with 24,25 ul Hi-DiTM Formamide (AB) and 
0,75 ul of GeneScan 500® LIZ Size Standard (AB). The mix was denatured at 95°C 
for 3 minutes, snap-cooled, and kept in ice water for 3 minutes until used for 
electrophoresis. For each run the identity of each allele was determined by 
comparison to the allelic ladder processed in parallel to samples.  
To distinguish allele peaks from technical artefacts and background noise a 
threshold was set at 50 relative fluorescence units (RFUs) [3, 4]. 
For all cases, the STR profile generated from ccfDNA was compared to the 
matching STR profile generated by DNA obtained from whole blood. 
Samples presenting artifactual peaks (i.e. stutter, pull-up from another dye) were re-
amplified and reanalyzed to obtain high quality reads for allele genotyping.  
 
 
Results and discussion  
Cell free nucleic acids (cfNA) is defined as extracellular DNA occurring in blood 
[5]. It is normally occurring in healthy people as well as in patients suffering from 
cancer [6] or other destructive diseases or physiological conditions such as 
pregnancy [7].  
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In 1947, when the presence of circulating cell free nucleic acids in human plasma 
and serum was first described this raised little interest [8]. Nowadays, with the 
increasing demand for non-invasive tests for molecular markers, cfDNA analysis is 
considered an important opportunity [9]. The progress in diagnostic applications of 
ccfDNA has been reported for uses ranging from pathological to physiological 
events, from cancer biomarkers, prognostic marker in trauma patients, and 
transplant follow-up to genetic prenatal diagnosis. In particular, non-invasive 
prenatal diagnosis (NIPD) through cell-free foetal DNA (ffDNA) is becoming 
increasingly important and its applications in prenatal diagnosis is reaching 
consensus in the scientific research community also for non medical applications, 
such as forensic ones [10].  
Current evidences suggest that in healthy subjects cellular apoptosis, in the largest 
part of haematopoietic cells [11-12] contributes to cfDNA found in plasma and 
serum. However, in sick subjects additional cell origins and mechanisms of release 
seem to play a role [13] such as lyses of circulating tumour cells [14] or even active 
release from lymphocytes [15].  
It has been shown that cfDNA has lower molecular weights than DNA derived from 
cellular blood or tissues: cfDNA of cancer origin is present in fragments which are 
multiples of 180 bp by gel electrophoresis [16], while in the circulation of pregnant 
women 86% of DNA of fetal origin is smaller than 201 bp [17]. 
The Qiagen DNA extraction method resulted in 1,1 ± 0,55 ng/ul cfDNA and of 78 ± 
13 ng/ul DNA from whole blood using RT PCR measurements. All blank extracted 
samples failed to produce any amplification. 
The STR amplification performed in order to obtain the profiles from cfDNA 
showed good signal strength, low background, and accurate allele identification. We 
reported that each of the amplified STR alleles from free DNA matched to the 
profiles obtained from genomic double stranded DNA from whole blood (Figure 1). 
Only differences in Relative Fluorescence Units (RFUs) were observed, being lower 
in cfDNA specimens in all cases.  
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Figure 1. STRs profiles of DNA from whole blood (a) and of cfDNA of the same subject (b) 
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The reduced height of the RFUs in the profiles from cfDNA was attributed to 
diminished performance of the multiplex PCR due to a naturally occurring DNA 
fragmentation and or degradation in plasma, with reduced primer sites for 
amplification. 
In the past, due to low concentrations in specimens of healthy persons cfDNA could 
not be detected with the limited analytical sensitivity of the methods at that time 
[18]. This is the reason of the erroneous conclusion that cfDNA was associated with 
pathological conditions only. The development and availability of new techniques 
improved sensitivity and resulted in detection also in healthy subjects [19].  
We chose to use the Qiagen method of DNA extraction specific for plasma, and in 
particular we took care to process blood samples within 1 hour of drawing: it is 
known that increasing concentrations of cfDNA are associated with longer time of 
blood storage at room temperature, particular when plasma is separated after 24 or 
48 hours of drawing [20].  
In conclusion, even if use of ccfDNA analysis is increasing, to the best of our 
knowledge no data are available concerning successful performance of STR 
amplification for identification profiling using cell free plasma as the matrix for 
DNA extraction. 
We report, that ccfDNA from plasma is present in sufficient quantity and quality to 
perform human forensic STR profiling: we demonstrated the possibility of 
attributing identity to equivocal individual plasma samples.  
We propose that plasma can be considered a useful matrix in cases of forensic 
interest where human identification is requested. We think of the following 
situations: (1) in case of a misattributed plasma sample in the era of a diagnostic test 
from plasma, especially in oncology, (2) on plasma samples routinely used in 
monitoring infectious diseases, and (3) in contested cases of toxicological analysis 
on plasma of forensic interest. 
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Abstract 
Molecular analysis of plasma DNA during human pregnancies has led to the 
discovery that maternal plasma contains both foetal and maternal DNA. Non-
invasive prenatal diagnosis is changing the landscape of prenatal testing: tests 
performed on free foetal DNA are already proven for foetal gender, rhesus D blood 
type and some Mendelian conditions (achondroplasia). 
The purpose of this study is to perform non-invasive prenatal paternity testing 
monitoring paternally inherited polymorphism STRs of forensic use on free foetal 
DNA from pregnant peripheral blood. 
Non-invasive approaches for paternity testing for forensic purposes are of 
increasing importance, such as in cases of rape resulting in pregnancy. 
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Introduction 
Circulating cell free nucleic acids have been detected in peripheral blood specimens 
of healthy subjects as well as in patients.  
Previously we demonstrated the applicability of cfDNA analysis in human 
identification, verifying short tandem repeats (STRs) PCR amplification in 
extracellular circulating DNA for human identification [1].  
Kinship and parental tests are usually performed by forensic laboratories using 
commercial kits for STR multiplex analysis. In these tests DNA is extracted from 
oral swabs or blood samples, but also banked pathological tissues may be used for 
this purpose [2].  
For prenatal paternity testing, in particular in case of rape resulting in pregnancy, 
the analysis could be performed on amniotic fluid or chorionic villi: however, (1) 
such samples can be obtained only after the 13th gestational week (GW) and (2) 
sampling is characterized by invasiveness, with a small but existing risk for both the 
pregnant woman and her foetus, as well as being stressful for the woman, with 
evident drawbacks.  
As these procedures carry a small but significant risk of pregnancy loss, a 
convenient non-invasive prenatal diagnostic approach has long been sought.  
With the aim to verify whether plasma DNA of pregnant origin can be used as 
matrix for prenatal paternity testing by amplification of STR loci used in forensic 
human identification we analyzed plasma DNA of 26 pregnant women and 
compared their STR profiles with the STR profiles of putative biological fathers of 
their children.  
 
 
Materials and methods 
Ethics 
The study has been approved by the Ethics Committee of the University - Hospital, 
Padova, Italy (No. 2105P) and consent to participate in the study was obtained from 
all subjects. The study protocol was conform the guidelines of the “World Medical 
Association Declaration of Helsinki - Ethical Principles for Medical Research 
Involving Human Subjects” adopted by the 18th WMA General Assembly, 
Helsinki, Finland, June 1964, as revised in Tokyo, Japan, 2004. 
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In order to obtain written consent from the couple pregnant women received 
counselling after which her approval of informed consent in all instances followed 
by that of her partner. During the preliminary counselling sessions it has been 
explained that the results of this research project would not become available 
neither to the pregnant woman nor to the couple.  
 
Samples collection  
Inclusion criteria: singleton pregnancy as determined by US examination and 
known gestational age.  
Exclusion criteria: fertilization in vitro embryo transfer (FIVET) pregnancy, 
previous or current hematologic or lymphatic diseases, foetal congenital anomalies, 
vaginal bleeding during pregnancy. 
Gestational age was in all cases determined by US before GW 15. The samples 
from the pregnant women were collected at 3 gestational time windows when the 
women come to the clinic for the US control: 
- range from 6 weeks to 13, 
- range from 14 weeks to 27, 
- range from 28 weeks to 40. 
Maternal blood will be used immediately after sampling. Post delivery cord blood 
or excess material from chorionic villi will be used for the preparation of foetal 
genomic DNA. All these materials will be stored at -70°C prior to DNA isolation. 
Plasma was obtained from peripheral blood of 26 pregnant women at different 
gestational ages. Specimens were numbered for anonymous work-up. 
A volume of 2 ml of whole blood was centrifuged at 4°C for 10 min at 1000x g 
(Heraeus Fresco 21 Centrifuge, Thermo Electron Corporation, Karlsruhe, DE) 
within one hour from drawing. The clear supernatant obtained after centrifugation 
was transferred to a new 2,5 ml micro tube, re-centrifuged at 4°C for 15 minutes at 
2,000x g to eliminate platelets in the plasma sample. There after all cells were 
removed and approximately 600ul of plasma was obtained. Three 15ul aliquots of 
each plasma sample were microscopically inspected and absence of cells was 
confirmed. 
TE buffer (10 mM Tris, 0,1 mM EDTA, pH 8,0) was used as blank of extraction 
every 5th samples. 1 mL of whole blood was drawn from the putative fathers. 
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DNA preparation and quantification  
cfDNA was extracted in two replicates from 200 ul of plasma with four negative 
controls (TE buffer) using a QIAamp Mini blood kit (Quiagen, Valencia, CA) 
according to the manufacturer’s protocol DNA purification from blood or body 
fluids (Spin protocol). The final elution volume was 100 ul. The eluted DNA 
samples from the same starting sample were combined, obtaining 200 ul of eluted 
DNA from each subject. cfDNA was stored at -20°C until further use. 
DNA Quantification was performed by real-time PCR (RT-PCR) using the relative 
quantification with a standard curve method. Albumin (gene) was used as reference 
and monitored on an ABI7900 sequence detection system using SDS Software v 
1.2..  
As control profile of pregnant women, their partner and baby, 100 ul of DNA from 
200 ul for whole blood sample or cord blood was obtained following the same 
extraction protocol.  
 
DNA profiling 
Genetic human identification analysis was performed by simultaneous PCR 
amplification of fifteen DNA STR autosomal loci and a sex determination marker, 
Amelogenin, covered by the commercial kit AmpFl STR NGM (AB). Autosomal 
STR loci (D3S1358, vWA, D16S539, D2S1338, D8S1179, D21S11, D18S51, 
D19S433, TH01, FGA, D10S1248, D22S1045, D2S441, D1S1656 & D12S391) and 
the sex specific STR locus were amplified from the extracted ccfDNA and DNA: 
the 29-cycle amplification was executed according to the original manufacturer’s 
protocol in a final reaction volume of 25 uL, composed of 10 ul SGM plus reaction 
mix, 5ul NGM primer set and 10ul of ccfDNA at concentrations ranging from 0,08 
to 0,1 ng/ul as measured by RT-PCR or 10ul of DNA at 0.1ng/ul concentration. 
Amplified fragments were resolved on an ABI Prism 310 Genetic Analyzer (AB) 
and genotyping was carried out using GenemapperID v3.2 software (AB). To 
distinguish allele peaks from technical artefacts and background noise a threshold 
was set at 50 relative fluorescence units (RFUs) [3, 4]. 
For all cases, the STR profile generated from ccfDNA was compared to the 
matching STR profile generated by DNA obtained from cord blood of the newborn 
and whole blood of the putative father. 
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Results and discussion 
Five percent of sexual assault crimes results in rape related pregnancy [5]. Up to 
day, prenatal paternity testing that could represent a guilt test, was only available 
from genetic analysis of material obtained through invasive sampling of chorionic 
villi and amniocentesis. The latter are both associated with a small but existing risk 
for both mother and child, that cannot justify the forensic aim of the exams [6].  
To our knowledge previous attempts based on cell-free foetal DNA demonstrated 
suppressed amplification of short tandem repeats (STR) of foetal alleles due to 
predominance of cell-free maternal DNA in these samples [7]. Here we performed 
an attempt to amplifying foetal alleles from pregnant women using the commercial 
kit AmpFl STR NGM (AB), different form the protocols used by others. The 
above kit employs shorter STR amplicons, which is expected to improve 
amplification of ff-DNA fragments. Recently, it has been shown that ff-DNA 
fragments in maternal plasma are smaller than mf-DNA [8].  
We extracted DNA from 200 ul of 55 maternal plasma samples and successfully 
amplified all maternal STR loci covered by the commercial kit used and validated in 
forensic casework. The literature reports [7] that Y-chromosome specific 
amelogenin in cases of male foetuses was amplified only sporadically. For the 
amplicon sequence we were not able to reproduce the results previously published 
by Wagner et al. with the AmpFLSTR Identifier kit. 
We consider two possible reasons for the failed amplification: first, the excess of 
plasma DNA of maternal origin suppresses the primer binding to the foetal plasma 
DNA, and second, the smaller length of the foetal plasma DNA can reduce the 
probability of primer binding. 
 
Conclusions  
Classical methods based on capillary electrophoresis that are used in forensic 
genetics for human identification through polymorphic STRs loci amplification can 
not be considered a useful approach to investigate foetal alleles on maternal plasma 
specimens during pregnancy because of primer binding suppression due to the 
excess of the pregnant allele fractions and due to the smaller size of the foetal 
fraction. Our results demonstrated that using smaller amplicon sizes there was no 
improvement of the multiplex reaction. 
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Finally, we retain that free foetal DNA analysis for forensic purposes needs to be 
investigated using other approaches. 
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Abstract 
The profiling of short tandem repeat (STR) loci is currently used in forensic 
genetics for identification purposes.  
We recently demonstrated the possibility to perform DNA profiling for 
identification purposes on plasma DNA also named cell free DNA. 
Our attempt to investigate foetal STR profiles from plasma DNA of pregnant 
women, carrying also a small proportion of cell free foetal DNA, with traditional 
STRs amplification and fragments length separation by capillary electrophoresis 
(CE) failled. Recently, it has been demonstrated that pyrosequencing has exceeding 
capacity of data generation and discriminatory power [1].  
Here we embarked on a journey of Next Generation Sequencing (NGS) on a DNA 
specimen from plasma of a pregnant woman. This new approach represents an STR 
profiling method based on the use of Roche Genome Sequencer Junior 454 Life 
Science Titanium simultaneously sequencing four STR loci of forensic interest. We 
found that 454 STR sequence data out put is composed of maternal and foetal STR 
sequences.  
 67 
Introduction 
Forensic DNA profiling is mainly based on the analysis of STR loci. They are typed 
by DNA fragment analysis using PCR-based forensic kits and multicolor 
fluorescent CE [2]. STRs investigated are correlated to a well-defined allelic ladder 
repeat number; however, occasional variant alleles are observed: so-called ?off-
ladder? variant alleles. In any case, analysis of the lengths of the PCR amplicons 
does not reveal information on small fractions of contaminating DNA or sequence 
variations, overlooking important sub-information.  
Recently, for research purposes sequencing methods based on clonal amplification 
by emulsion polymerase chain reaction (emPCR) followed by pyrosequencing have 
been investigated [3].  
The pyrosequencing technology is based on detection of pyrophosphate (PPi) 
released as a result of dNTP incorporation. Nucleotides are added stepwise and if 
incorporated, PPi is released and used as a substrate for ATP sulfurylase forming 
ATP. Light is emitted when luciferase uses ATP to convert luciferin to its oxi-
derivative. Any excess of dNTPs is degraded by apyrase prior to addition of a new 
nucleotide. The out-put sequence is shown in a pyrogram where peak heights are 
proportional to the number of incorporated nucleotides [4]. Pyrosequencing has 
been used for a variety of applications, mutation detection of disease associated 
genes above all.  
Here, we sequenced for the first time four STR loci (Amelogenin, VWA, D8S1179 
and D1S1656) using the Genome Sequencer (GS) Junior 454 platform on plasma 
DNA of a pregnant woman and DNA from blood of her partner. We examined the 
feasibility of applying Roche GS 454 to STR typing for the purpose of forensic 
genetic investigation by directly comparing sequence data generated on the GS 454 
platform to conventional CE-based methods. We successfully detected sequences of 
foetal?s alleles in the maternal plasma DNA, confirmed by classical STR profiling 
of the newborn after delivery. 
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Materials and methods 
PCR amplification and capillary electrophoresis 
The DNA of a pregnant woman and the DNA of her partner had been profiled in a 
25 ul reaction volume using the commercial STR kit for forensic identification 
profiling (AmpFlSTR? NGM kit, Applied Biosystems, Foster City, CA, USA) 
following the manufacturer?s protocol. 
At delivery, a sample of cord blood had been profiled as well. 
DNA specimens were extracted using the QIAamp Mini blood kit (Quiagen, 
Valencia, CA) according to the manufacturer?s protocol DNA purification from 
blood or body fluids (Spin protocol). 
The PCR products were visualized on an AB Prism 310 Genetic Analyzer (Applied 
Biosystems). CE profiles of parents and newborn are shown in Table 1. 
 
 
 
 
 
 
Table 1: CE profiles of mother?s to be (M), presumptive biological father (P) and newborn (F). the 
four STRs indicated in grey were used for the deep sequencing approach. 
 
The allele calls determined by the AmpFlSTR NGM Amplification kit were used 
for comparison with the pyrosequencing data. 
Locus M P F 
D22S1045 15 15 15 
D19S433 12/16 12/14 14/16 
TH01 9/9,3 8/9 8/9 
FGA 20/21 20 20 
D2S441 11 10/12 10/11 
D3S1358 16/17 17/18 16/17 
D1S1656 13/17,3 12/16 12/13 
D12S391 16/19 15/18 18/19 
D10S1248 14/18 16 16/18 
VWA 14/18 16/19 14/16 
D16S539 11/12 11 11 
D2S1338 17/20 17/25 17 
D8S1179 9/16 11/15 9/15 
D21S11 28/31 29/31,2 28/31.2 
D18S51 13/17 14/17 14/17 
Amelogenin XX XY XY 
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GS 454 sequencing 
The plasma DNA of the pregnant woman and the DNA of her partner were 
sequenced for 4 STR loci (Amelogenin, VWA, D8S1179 and D1S1656) on 454 GS.  
The plasma DNA specimen of the pregnant woman and the DNA from whole blood 
of her partner were extracted within the first hour from withdrawal using the 
QIAamp Mini blood kit (Quiagen, Valencia, CA) according to the manufacturer?s 
protocol DNA purification from blood or body fluids (Spin protocol). Amplicon 
libraries were prepared using PCR amplification with specific fusion primers using 
the FastStart High Fidelity PCR System, dNTP Pack (Roche) following 
manufacterer?s instructions [Amplicon Library Preparation Method Manual GS 
Junior Titanium Series (March 2012)]. 
The following primer sets for template specific sequences were used to design the 
fusion primers for library preparation as indicated at 
http://www.cstl.nist.gov/strbase/multiplx.htm: 
 
AME FW : 5? CCCTGGGCTCTGTAAAGAATAGTG 3? 
AME RW : GCTTAAACTGGGAAGCTG 
 
VWA FW : CCCTAGTGGATGATAAGAATAATCAGTATG 
VWA RW : GACAGATGATAAATACATAGGATGGATGG 
 
D8S1179 FW TTTTTGTATTTCATGTGTACATTCG 
D8S1179 RW : CGTATCCCATTGCGTGAATA 
 
D1S1656 FW: GTGTTGCTCAAGGGTCAACT 
D1S1656 RW : GAGAAATAGAATCACTAGGGAACC 
 
All samples were PCR amplified using designed fusion primers composed of three 
parts fused together:  
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- 5’-portion of 25-mer called adaptator, for the binding to the DNA Capture Beads 
(Lib-A) and for annealing the Emulsion PCR (emPCR) amplification primers and 
the sequencing primer; 
- 3’-portion to anneal with the specific sequence of interest; 
- Multiplex Identifier (MID) used to “barcode” the samples, that allow the 2 
samples to be pooled and sequenced together. 
EmPCR (Lib-A kit) and subsequent bead-enrichment and sequencing steps followed 
manufacturer?s instructions [GS Junior Titanium Series emPCR Method Manual 
(March 2012) and GS Junior Titanium Series Sequencing Method Manual 
(November 2012), respectively]. 
 
Data sorting 
The sequence reads were first sorted by MID tag into the original 2 libraries using 
linux command.  
The .sff files generated by GS Junior 454 were converted in FASTA format. 
Furthermore, we used BLASTClust to cluster sequences with a stringency identity 
of 100%. Using a Perl script we counted the number of sequences grouped in each 
cluster to estimate the coverage of identical sequences. 
Sequences were aligned with a reference and STRs were identified. To align reads 
with the reference we used Amplicon Variant Analysis Sofware and Mapper 
Software (Roche). 
 
Results and discussion 
A total of 110815 sequence reads were successfully aligned with the references. A 
median of 15512 reads were obtained per amplicon in each of the two samples. No 
reads were obtained for STR D8S1179 in the mother?s to be sample.  
Amelogenin STR locus 
For the sample of the putative father, in the Amelogenin locus next to 50% of allele 
X and Y were obtained (5712 and 5962 reads, respectively), confirming the 
robustness of the technology. For the sample of pregnant woman, only X allele 
sequences were obtained. Y allele sequences were not found. Even if the Y allele of 
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the foetus was expected, deep sequencing did not show the corresponding sequence. 
Amelogenin amplification on nucleated red blood cells of foetal origin (see Chapter 
5) failed, demonstrating a low performance of the Amelogenin sex marker. 
D1S1656 locus 
The sample of the putative father showed a next to equal proportion between allele 
12 and allele 16, as also called by CE. The deep sequence analysis showed that the 
CE called allele 12, with sequence motif [TAGA]12 [TG]5, has indeed a different 
composition in bases: it presents an overlapping size to the CE 12th (133bp length) 
but the deep sequencing analysis revealed its base composition in 
[TAGA]11[TAGG][TG]5, described as the 12? allele. 
The mother?s to be plasma DNA sample had three alleles at the D1S1656 locus: 
-7423 sequences corresponding to allele 13, also present at the mother?s CE profile 
(Table 1) 
-10529 sequences corresponding to allele 17.3, also present at the mother?s CE 
profile (Table 1) 
-7017 sequences corresponding to allele 12?, present in the deep sequencing profile 
of the putative father and by deduction there of belonging to foetal DNA.  
Note that CE data of the newborn showed the D1S1656 locus profile 12-13, where 
the allele 12 corresponded to the allele 12 of the mother?s partner CE profile. 
The obtained data did not show the aspected proportion 95:5 of pregnant to foetus 
cfDNA fragments, as discussed by Lo and collegues in 1998 [5]. 
VWA locus 
The sample of the putative father showed a next to equal proportion of sequences 
corresponding to allele 16 and allele 19, as reported on CE analysis, confirming the 
expected proportion between the two alleles. 
The mother?s to be sample is triallelic for this locus, confirming the CE profiling for 
the two maternal alleles, with the addition of a small proportion of a thirth allele: 
-7512 sequences of allele 14? 
-3852 sequences of allele 18? 
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-53 sequences correspondig to allele 16, also present in the profiling of the putative 
father and of the male newborn, by deduction there of belonging to foetal DNA.  
Also in this case the relative quantity of abtained sequences seems to rebut the 
proposed proportion of mother?s to be and foetus cfDNA [5]. 
D8S1179 locus 
The sample of the putative father presented about 50% of allele 11, and 43% of 
allele 15, confirming the CE profiling. In addition, the pyrosequencing analysis 
revealeded that allele 15 is equal in length to CE allele 15th, but presents a different 
sequence due to the presence of 2 single nucleotide polymorphisms (SNPs) (Figure 
1). The published sequence of the 15th allele is: 
TCTA TCTG [TCTA]13 
while the GS 454 sequence obtained is 
TCTA TCTA TCTG [TCTA]12 
SNPs indicated in red. 
The identification of the SNPs variants increases the identification and 
discriminatory power in case of alleles with the same length. 
 
 
 
 
 
Figure 1: Frequencies distribution of variant reads of putative father?s D8S1179 locus. Bars indicate 
relative quantities of specific variations aligned with the reference. In grey, bars with ?deletion? of 
tetraplets corresponding to allele 11 (percentage of variations: 50%), in green and black, bars with 
SNPs calling compared to reference corresponding to allele 15 (green G>A conversion and black 
A>G conversion).  
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In the sample of the pregnant woman no reads corresponding to alleles D8S1179 
were obtained. Due to the lack of amplification of this locus we cannot draw 
conclusions about the performance of 454 GS for this locus. We speculated that the 
absence of reads for locus D8S1179 could be due to the low quality of the specific 
DNA fragments. 
 
Our preliminary 454 data were promising in terms of total data recovery. In the 
presumptive biologic father?s DNA we obtain equal distribution of reads. In 
mother?s to be plasma DNA we obtained an imbalanced reads ratios among the four 
loci, with no reads for the D8S1179 locus and none for the Y reads.  
We considered that plasma DNA is highly degradated and fragmented, and, 
moreover, that foetal fragments are present in very small percentages among the 
pregnant plasma. 
It has recently been demonstrated that the deep sequencing approach and data 
analysis produced reliable results, comparable to the CE approach [6]. In fact, PCR-
based fragment analysis and CE provide amplicon lengths, that are used to estimate 
the number of STR repeat units to determine allele identity, but do not allow a 
complete base composition resolution. STR base composition could be investigated 
only with sequencing approaches and provided additional information. 
In forensic context up to now presentation of data obtained with next generation 
sequencing technology based on clonal amplification by emPCR followed by 
pyrosequencing have focused on the discriminating power of detecting loci with 
overlapping amplicon size ranges [1]. Moreover, even if sequence data for STR can 
also be generated using the classical Sanger method, this method is not used in 
routine practice in forensic genetics, because of the extremely laborious workup. 
The simplicity of simultaneously typing multiple samples for a number of STR loci 
amplicons and resolution of its basepair composition underlines the benefits of next 
generation sequencing for forensic applications. 
With our preliminary results, even if further optimization of the multiplex 
amplification is necessary to correct the imbalance, we demonstrated for the first 
time that foetal STR profiles could be investigated with next generation deep 
sequencing on plasma DNA of pregnant women. 
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The sequence data and resulting aligned reads were more than sufficient to reveal 
sequence variation among sample. SNPs were observed, introducing an opportunity 
for discrimination of alleles not available with commercial kits.  
We retain that this approach has great promise and should be developed for 
application in forensic genetics. It seems to be promising in STR allele 
discrimination also in contaminated samples thanks to the extra-value of 
distinguishing also DNA base substitutions and sequence variations which would 
not have been otherwise identified using conventional STR typing. 
STR sequencing on the 454 platform could represent a good approach to perform 
non-invasive prenatal paternity testing on cf DNA in rape-related pregnancies. 
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Abstract 
Introduction and aim  
Currently, prenatal genetic analysis is limited to invasive approaches on amniotic 
fluid or chorionic villi. A convenient non-invasive prenatal diagnostic approach has 
long been sought. Genetic prenatal diagnosis can have forensic applications, in 
particular in cases of rape-related pregnancy. We report preliminary results of a 
non-invasive prenatal paternity test on circulating foetal cells of peripheral blood of 
pregnant women. 
Materials and methods 
Pregnant blood samples were taken at various time points during pregnancy. 
Fluorescent Activated Cell Sorting (FACS) using a combination of monoclonal 
antibodies was used to enrich nucleated red blood cells of embryonic and foetal 
origin. After delivery a sample of cord blood was taken as newborn control. DNA 
was extracted from blood of the parental couple; nucleated red blood cells of foetal 
origin, and of newborn and genetic profiles were obtained and analyzed.  
Results and discussion 
In one case comparison of the genetic profiles showed that all amplified foetal 
alleles from nucleated red blood cell of embryonic origin matched the alleles of 
their putative fathers. We carried out a non-invasive prenatal paternity testing on 
DNA of rare foetal cells circulating in pregnant blood. This is the first report on 
nucleated foetal red blood cell analysis for forensic purpose. 
 79 
Introduction 
Prenatal genetic testing can be performed only on embryonic or foetal material. 
Such material can be obtained only invasively on amniotic fluid and chorionic villi 
samples after the 13th gestational week (GW) or on foetal blood samples after 20th 
GW. From pregnant women’s blood specimens there is ample evidence of 
circulating fragmented free foetal DNA [1] that would permit early non-invasive 
prenatal sex determination also for medical applications [2]. 
Above all, invasive sampling is characterized by a small but existing risk for both 
pregnant women and their foetus [3 – 5], as well as being stressful for women, with 
evident drawbacks. As these procedures carry a small but significant risk of 
pregnancy loss, a convenient non-invasive prenatal diagnostic approach has long 
been sought, but rarity of foetal cells, however, has made the development of such 
approaches very challenging. 
However, non-invasive prenatal diagnosis (NIPD) is becoming increasingly 
important and its application in prenatal diagnosis is reaching consensus in the 
scientific research community. In addition non-invasive prenatal testing for non-
medical purposes, including forensic genetics is gaining attention. In relation to 
non-invasive prenatal testing we discussed ethical issues arising from non-medical 
applications of NIPD, such as sex determination and paternity testing in earlier 
gestational age and subsequent offspring selection [6]. Nucleated red blood cells of 
foetal origin circulating in pregnant blood can represent an alternative candidate 
source of foetal DNA: NRBCs contain a true representation of the foetal genotype 
[7]. 
Thus, aiming to verify whether foetal polymorphic STR loci used for forensic 
analysis can be amplified from nucleated red blood cell isolated from pregnant 
blood to confirm the foetal cell identity, we performed genetic STR profiling on 
NRBCs obtained with Fluorescence Activated Cell Sorting from maternal blood. 
We performed also paternity testing comparing DNA isolated in sorted cells to 
those of the putative fathers. We retain that the foetal origin of the NRBCs needs to 
be fully confirmed prior to any genetic analysis for prenatal testing.  
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Materials and methods 
Ethics 
The study obtained approval of the Ethics Committee of the University - Hospital of 
Padova (Protocol n. 2105 P), Italy. Consent has been obtained from all subjects of 
the couples enrolled. The study protocol has been qualified conform the ethical 
guidelines of the “World Medical Association Declaration of Helsinki—Ethical 
Principles for Medical Research Involving Human Subjects” adopted by the 18th 
WMA General Assembly, Helsinki, Finland, June 1964, as revised in Tokyo, Japan, 
2004. 
 
Enrollment of the couples 
Twentysix couples of pregnant women and their partners were enrolled in the study. 
A total of 55 blood samples of pregnant women and 26 blood samples of their 
partners were collected (sampling period of gestation was between 6 gestation 
weeks –GWs- and 36 GWs + 6 days) attending the Section of Obstetrics and 
Gynecology Azienda Ospedaliera of Padova (Italy) between 2011 and 2012, under 
information and consent at first of the pregnant women and after that of the putative 
fathers with the specification that no results of paternity testing would be 
communicated to the couple  
At each obstetric monitoring seven milliliter of pregnant woman peripheral venous 
blood was collected, while one blood spot of the putative fathers was collected at 
the beginning of the recruitment. All samples from the pregnant women were 
collected into ethylenediamine tetra-acetic acid (EDTA) tubes, all taken before any 
invasive procedure (amniocentesis or corial villi sampling) and processed within an 
hour of collection. After the delivery 200 microliter of cord blood were taken.  
 
Enrichment of the foetal nucleated red blood cells from pregnant peripheral blood 
A double discontinuous density gradient of Ficoll was used in order to enrich the 
foetal nucleated red blood cells through a syringe and spinal needle apparatus 
according to D’Souza et al. [8] with the following differences: five millilitres of 
1,073 g/ml solution of Ficol Plaque were poured through the syringe into a 50 ml 
Polypropylene Conical Tubes (Falcon) followed by 5 ml of the 1,085 g/ml of 
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Ficol Plaque solution; then 14 ml of 1:1 solution of maternal blood and 0.9% NaCl 
was poured through the syring layering the blood solution onto the gradient. The 
tube was centrifuged at 3,000 g for 30 min (Megafuge 1.0R, Heraeus, Hannau, 
Germany) without brake. The cells at the interphase of the two gradients (Figure 1) 
were collected and washed once with 10 ml of Running Buffer (PBS, 0,5% BSA, 
0,5% EDTA). 
 
 
 
Figure 1. The cell layer at the interface (arrow) contains the enriched fraction of NRBCs. 
 
 
Permeabilization and staining procedures  
Following enrichment, the cells were permeabilized and stained with monoclonal 
antibodies according to the Fix & Perm protocol (Invitrogen, USA). The staining 
protocol required the preliminary division into 3 aliquots of 100 µl of cell solution: 
1. aliquot was not stained using the blank cells for instrument calibration; 
2. aliquot was stained with the isotype controls 5 µl IgG –Phycoerythrin (PE) (Cat: 
CYT-IC004F, Cytognos, Salamanca, Spain) and 5 µl IgG 2b-Fluorescein 
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isothiocyanate (FITC) (Cat: CYT-IC004F, Cytognos, Salamanca, Spain) also used 
for instrument calibration; 
3. the third aliquot was stained with a set of three antibodies: 5 µl CD45-peridinin 
chlorophyll protein (PerCP) (Clone: 2D1, Cat: 347464, BD Pharmingen, San Diego 
CA), 10 µl CD71-PE (Clone: M-A712, Cat: 555537, BD Pharmingen, SanDiego, 
CA) and 10 µl anti-HbF-FITC (Clone:2D12, Ct:552829, BD Pharmingen, 
SanDiego, CA). The cells were stained for 20 min at room temperature in the dark. 
 
Sorting of the cells 
The BD-FACSAria III flow cytometer, equipped with three lasers (488, APCand 
UV) (Becton Dickinson, San Jose CA, USA) was used for cell sorting. Prior to 
acquisition, the blank cells and the isotype controls were used to subtract auto-
fluorescence. Firstly the CD45 negative cells were selected and from these dual 
positive CD71 and anti-HbF cells were sorted in 20 µl sheath fluid i.e. running 
buffer.  
 
DNA preparation and profiling 
DNA was extracted from 200ul of blood of the parental couple and of cord blood of 
the newborn using a QIAamp blood kit (Quiagen, Valencia, CA). DNA from sorted 
nucleated red blood cell of foetal origin was obtained using Kapa Express Extract 
(KapaBiosystem, Boston, US) with the following changes: extraction volume of 
20ul, instead of 100ul (1), precipitation with ethanol and sodium acetate (500 ml 
EtOH,20 ml NaAc 3M, pH 5.2 20), and two EtOH 70% washing, final elution in 10 
ul of DNAse free water. 
Genetic human identification analysis was performed by simultaneous PCR 
amplification of fifteen DNA STR autosomal loci and a sex determination marker, 
Amelogenin, using the commercial kit AmpFl STR NGM (Applied Biosystems), 
in 12,5 ul of total volume. Autosomal STR loci (D3S1358, vWA, D16S539, 
D2S1338, D8S1179, D21S11, D18S51, D19S433, TH01, FGA, D10S1248, 
D22S1045, D2S441, D1S1656 & D12S391) and the sex-determining STR locus 
(Amelogenin) were amplified from the extracted DNA: the 29-cycle amplification 
was executed according to the original manufacturer’s protocol in a 25ul final 
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reaction volume, consisting of 10 ul SGM plus reaction mix, 5ul NGM primer set 
and 10ul of DNA at concentrations of 0,1 ng/µl as quantified by RT-PCR. Human 
Control DNA 007 (0,1 ng/µl) provided by the manufacturer’s kit AmpFl STR 
NGM served as control DNA. The negative controls were represented by the TE 
Buffer samples previously extracted. All amplifications were performed on DNA 
thermal cyclers (GeneAmp PCR System 9700, Applied Biosystems). Amplified 
fragments were resolved on an ABI Prism 310 Genetic Analyzer (Applied 
Biosystems) and genotyping was carried out using GenemapperID v3.2 software 
(Applied Biosystems). Electrophoresis was run using a 50 cm capillary and POP-4 
polymer (Applied Biosystems) by mixing 1,5 ul of the PCR product with 24,25 ul 
Hi-DiTM Formamide (Applied Biosystems) and 0,75 ul of GeneScan 500® LIZ Size 
Standard (Applied Biosystems). The mix was denatured at 95°C for 3 minutes, 
snap-cooled, and kept in ice water for 3 minutes until used for electrophoresis. The 
identity of each allele was determined by comparison to the allelic ladder processed 
in parallel to samples for each run. Allele peaks were measured as relative 
fluorescence units (RFUs) and interpreted when peak height was greater than (or 
equal to) 50 RFUs. STR profiles generated by using DNA from NRBCs were 
compared to STR profile generated by DNA of cord blood of the newborn.  
 
 
Results  
During the sampling period ranging from 6 GW to 36 GW+ 6 days the number of 
samples obtained per pregnant women varied from one to 3 samples per woman. 
Three women (M3, M5, M20) withdrew consent to genetic analysis and profiling 
comparison with the partner half way the study participation period. One woman 
lost her pregnancy at 12 GW (M22). Four women moved to other obstetric units and 
delivered in other delivery centres (M2, M19, M21, M24), giving up participation to 
the research. Eleven women delivered in the emergency room during night and no 
cord blood samples were collected (M4, M6, M11, M12, M13, M14, M19, M24, 
M26, M27, M28, M29). Cord blood of 6 newborns was collected. 
 
The amount of negative CD45 and double positive CD71 e HbF events sorted 
varied along the pregnancy. Starting from the 8th GW in one case we obtain 300 
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events; before this gestation age no events was obtained in any of the samples. From 
300 sorted events, no DNA amplification or profile was obtained. We observed an 
inter-individual variability and an intra-individual variability in the numbers of 
sorted events (Table 1).  
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Table 1. Fetal NRBCs isolated using FACS and CD 45 negative gate, CD 71 and Anti-HbF dual 
positive over on three gestational period. HbF- is equal to No HbF positive cells. 
Trimester Identification  
No. of case 
Percentage of NRBCs  
from enriched cells (%) 
No. of NRBCs isolated 
First  
(0-13 GWs) 
M6.1 
M11.1 
M13.1 
M15.1 
M15.2 
M17.1 
M17.2 
M19.1 
M22.1 
M24.1 
M25.1 
M26.1 
M27.1 
M27.2 
M28.1 
M28.2 
M29.1 
0.1 
- 
0.02 
0.001 
0.015 
0.005 
0.006 
0.007 
- 
0.003 
0.038 
0.027 
0.015 
0.039 
0.1 
0.01 
- 
5570 (HbF-) 
- 
458 (HbF-) 
425 
1000 
300 
137 
499 
- 
403 
249 
313 
515 
305 
5000 (HbF-) 
21 
- 
Second (14-
27 GWs) 
M3.1 
M4.1 
M4.2 
M4.3 
M5.1 
M6.2 
M6.3 
M8.1 
M8.2 
M9.1 
M10.1 
M10.2 
M11.2 
M11.5 
M12.1 
M12.2 
M13.2 
M13.3 
M14.1 
M14.2 
M17.3 
M19.2 
M20.1 
M21.1 
M21.2 
M24.2 
M29.2 
0.6 
0.1 
0.01 
0.001 
0.01 
0.1 
0.014 
0.035 
0.038 
0.012 
0.04 
0.15 
0.007 
0.01 
1.5 
0.2 
0.028 
0.016 
0.007 
0.025 
0.010 
0.003 
- 
0.004 
1.1 
0.022 
1.2 
14187 (HbF-) 
14440 (HbF-) 
6200 (HbF-) 
42 
1931 (HbF-) 
2692 (HbF-) 
1737  
103 
94 
54 
807 (HbF-) 
1546 (HbF-) 
120 
7780 (HbF-) 
79000 (HbF-) 
1797 
797 
95 
410 
490 
1162 
73 
- 
50 
11400 (HbF-) 
2972 
155000 (HbF-) 
Third (28-
40 GWs) 
M8.3 
M9.2 
M9.3 
M10.3 
M14.3 
M15.3 
M23.1 
M23.2 
M25.2 
M26.2 
M27.3 
0.021 
0.018 
0.12 
0.011 
1.1 
1.4 
0.011 
0.005 
0.5 
0.8 
1.2 
485  
202 
2513 (HbF-) 
143 
50340 (HbF-) 
85000 (HbF-) 
584 
850 
34400 (HbF-) 
36000 (HbF-) 
21000 (HbF-) 
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During the first trimester the amount of NRBCs in maternal circulation varies 
between 0,003 % to 0,039 % of the total cell population and from 21 to 1000 cells 
by counting the events at the sorter. We noted that in all samples (55) but six HbF 
positive cells were present. In cases lacking HbF we sorted CD45 negative cells 
contemporary with CD71 positive cells raising the total number of events to a 
maximum 5000 events, and in all cases when a STR profile was obtained it 
indicated only maternal alleles.  
In the second trimester, from the third sample of the subject M17 (M17.3, 15 + 4 
GWs) we obtained valid STR amplification from 1162 sorted events with alleles 
matching with those of the putative father and with the ones of the new born cord 
blood at delivery. The profile obtained from sorted NRBCs was a mixture of the 
pregnant woman and the foetus she was carrying (Figure 1). Unfortunately only one 
peak for the sex determination marker Amelogenin was obtained instead of two 
which were expected for the male born (Figure 2). 
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Figure 1. Comparison between profiles of mother (M17), upper electropherogram, her partner (P17), 
middle, and the profile obtained from CD45 negative, CD 71 and HbF dual positive cells sorted after 
enrichment from pregnant peripheral blood at 15 + 4 GW (1062 sorted events). 
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Figure 2. STR profile from cord blood of F17. 
 
 
Discussion  
Foetal-maternal trafficking results in the presence of foetal cells and circulating free 
foetal DNA in the maternal circulation throughout pregnancy. In the last years 
efforts have been made to isolate foetal genetic material from pregnant blood, 
especially foetal nucleated cells with genomic DNA of the foetus. NRBCs represent 
a potential source of foetal genetic material for non-invasive prenatal diagnosis [9]. 
However the isolation of an adequate numbers of a pure foetal cells has up to now 
shown to be very challenging. 
Nucleated red blood cells are immature erythrocytes present in the foetal 
circulation, in foetal placental vessels and also in the maternal circulation [10 - 11]. 
Invasive prenatal sampling, such as amniocentesis, chorionic villi sampling or foetal 
blood sampling, are currently the only ways to perform prenatal genetic testing and 
these sampling methods pose a not negligible risk both for the pregnant and the 
foetus. Moreover these risks cannot be accepted for non-medical requests of genetic 
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testing, such as prenatal paternity testing or sex determination. In particular, for 
forensic purposes invasive genetic testing of foetuses is not permitted because of the 
minimal but existing risk of pregnancy loss, lacking clinical benefits neither for the 
mother nor for the foetus [12]. So, aiming to demonstrate foetal origin of circulating 
cells in order to permit prenatal genetic diagnosis we attempted to amplify foetal 
alleles of paternal origin from nucleated red blood cells of foetal origin circulating 
in maternal blood during pregnancy.  
To confirm the profile we compared it with that of the putative father, performing a 
non-invasive prenatal paternity testing. The comparison was also extended to the 
samples of the newborn at delivery and the previous finding was confirmed. 
Previous studies reported attempts to amplify validated STRs for paternity testing in 
pregnant plasma, but successful amplification of all autosomal foetal alleles of 
paternal origin has not been shown. Only the Amelogenin locus with sporadic 
amplification of other loci has been shown in these studies [13]. 
We isolated NRBCs by FACS after preliminary enrichment with a double density 
gradient and then by selection of CD71 (transferrin receptor) –positive and HbF 
(foetal hemoglobin) in the CD45 negative gate, leaving only erythroid cells and 
platelets [14 – 15]. The partial foetus profile obtained from 1162 sorted events from 
the CD45- CD71+ and HbF+ gate of enriched cells demonstrated for the first time 
the unquestionable origin of foetal cells. Autosomal loci of foetal origin amplified 
sporadically: we did recognize that the sorted events included also maternal cells, as 
demonstrated by the profile including maternal alleles not present in the cord blood 
of the newborn. The limitation in this sorting protocol arises from the lack of a 
specific antibody that would allow to isolate a pure foetal cell population. We had 
chosen a combination of monoclonal antibodies according to D’Souza et al. [8]. The 
poor results obtained in our study can be attributed to (1) the small amount of DNA 
obtained from NRBCs and (2) the presence of contaminating maternal DNA due to 
lack of high specificity of isolated erythroblasts of foetal origin. 
 
Conclusions 
Even if there is not doubt that foetal cells subsist in the maternal circulation, 
features that distinguish these foetal cells from the maternal ones need to be 
explored further in order to provide a reliable tool of non-invasive prenatal 
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diagnosis. NRBCs fingerprinting needs to be deeper investigated prior to validation 
of non-invasive prenatal genetic testing. This approach represents also a new tool in 
forensic genetics, when invasive sampling is not ethically accepted: par example in 
cases of paternity testing in pregnancies resulting from rape or in wrongly attributed 
samples of in vitro fertilization.  
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CONCLUSIONS  
Rape-related pregnancy occurs with significant frequency. It is a cause of many 
unwanted pregnancies and is closely linked with family and domestic violence, but 
also extra-domestic violence plays an important role in sexual assault and 
subsequent unwanted pregnancy. Great attention and efforts should be aimed at 
prevention but also identification of unwanted pregnancies that result from sexual 
victimization need more consideration. The identification of rape-related pregnancy 
is required for the persecution of the perpetrator by the law. 
In 1996 Holmes et al. reported that 5% of women who are raped become pregnant, 
which resulted in an estimated 32.000 rape related pregnancies in the United States 
annually [1].  
Prenatal paternity determination can be performed only by invasive procedures, 
such as sampling of chorionic villi, amniocentesis or cordocentesis that carry a 
small but existing risk both for the pregnant woman and for the foetus. 
The existing risk of invasive procedures is not acceptable for forensic requirement, 
such as the identification of the perpetrator in case of rape-related pregnancy, 
excluding the possibility to perform a risky procedure for justice benefits. 
Since significant progress in molecular biology have brought non-invasive prenatal 
diagnosis (NIPD) to a point where it is now in common use, a non-invasive 
approach also for non medical applications of paternity testing came into sight. 
Generally speaking NIPD offers opportunities with specific ethical qualities; firstly, 
safety; secondly early detection and last but not least NIPD is characterized by easy 
sampling using a simple blood drawing. All these features together ease of access of 
non-invasive prenatal testing also for non-medical causes such as sex determination 
and non-invasive prenatal paternity testing (NIPPT).  
Sex determination can be clinically relevant in cases of sex-linked diseases of the 
foetus, but it can also be used for non-clinical motivated sex selection. Questions 
are arising within the ethical debate regarding to use of new reproductive 
technologies for selecting the sex of one’s child before implantation [2]. According 
to Italian law (L. 40/2004) the selection of embryos on the basis of sex is not 
permitted, but for the interruption of a pregnancy after embryo transfer – in case of 
in vitro fertilization – (before the 90th day according to Italian law L 194/1978) it is 
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permitted for maternal reasons, and could include sex selection. The latter choice 
needs to be valued as a reproductive autonomy of the mother’s to be. 
Male foetuses sex selection follows the preference in some societies of giving birth 
to a boy over a girl: this discrimination of women constitutes an injustice that 
should be prevented [3]. Moreover, large-scale execution of male selection could 
undermine a public good reinforcing a bias in the ratio between men and women 
[4]. 
Concerning NIPPT, three major non-medical applications can be considered: 
surveying the perpetrator in pregnancy as the result of a rape (a), unsure paternity in 
case of women with multiple partners (b), unsure paternity in case of suspect of 
erroneous embryo transfer (c). 
In the first case, paternity testing is neither questioned nor disputed. It serves 
forensic requirements and allows interruption of pregnancy if required by the 
pregnant woman, even if this might raise religious objections. 
Concerning ambiguous paternity, some additional considerations need to be made. 
Refusing to perform paternity testing in these cases is moralistic and unprofessional: 
such inference in the life of women reflects an illicit sentence of licentious life, 
which is not the assignment of a physician. The denial of access to NIPPT could 
have other ethically non-acceptable implications for the woman involved. A 
pregnant woman in case of ambiguous paternity could decide to terminate the 
pregnancy anyhow, or on the other hand decide to continue pregnancy with 
remaining uncertainty about the kinship. Another questionable implication of this 
position favours the expansion of services or laboratories that provide paternity 
testing without legal, deontological or ethical guarantees. Paternity testing typically 
postnatal paternity testing is performed by private or and academic laboratories, 
after direct contact with the applicants. Even if also paternal consent in postnatal 
paternity testing is required a number of laboratories offer via the wwweb paternity 
testing without any guarantee regarding consent and privacy [5]. This practice is 
likely to extend to prenatal paternity testing in a near future. A long this line NIPPT 
will become available through the wwweb with the risk of lesion of privacy and 
consent rights of involved subjects. 
For these reasons we retain that empirical research into pregnant women’s attitudes, 
needs and preferences are necessary for the debate and decision-making process. 
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The non-invasive approach in prenatal diagnostics is feasible by the presence of 
cells and DNA fragments of foetal origin in the maternal circulation both in the 
whole blood and plasma fraction. 
With the aim to investigate the possibility of performing a NIPPT for forensic 
purposes we obtained the approval of the Ethics Committee of the University - 
Hospital of Padova (Protocol n. 2105 P / 2010), Italy.  
Our first approach was on free foetal DNA. In order to investigate the possibility to 
perform a human identification test on so called plasma DNA (or circulating cell 
free DNA), we firstly demonstrated the feasibility of fingerprint profiling based on 
STRs of common use on DNA extracted from cell free plasma: complete STR 
profiles where obtained from all ‘cell free’ plasma samples of volunteers enrolled in 
this preliminary approach. We noted that comparing the fingerprint profiles from 
whole blood and corresponding plasma, lower RFUs in cfDNA specimens were 
obtained in all cases even if the same quantity of DNA was explored. We attributed 
this result to the diminished performance of the multiplex PCR due to a naturally 
occurring DNA fragmentation and or degradation in plasma, with reduced available 
primer sites for amplification. 
When we investigated the cell free DNA of the pregnant women’s plasma at 
different gestational ages aiming to enable non-invasive paternity testing on free 
foetal DNA, we did not obtain STR allele amplification other than that of the 
pregnant women. Amplification of foetal alleles were apparently suppressed by the 
presence of maternal cell free DNA, even if we performed our test with AmpFlSTR 
NGM (AB), a sophisticated multiplex PCR, validated for degraded samples. We 
opt for these methods, being recently shown that ffDNA molecules in maternal 
plasma are smaller than mfDNA [6]. The next-generation chemistry of the used kit 
is considered capable of producing more discriminating DNA profiles on a wider 
number of samples. Such a chemistry would facilitate data sharing initiatives 
through the inclusion of new, highly discriminating, shorter STR loci to maximize 
performance on degraded and challenging samples, such as plasma DNA is to be 
considered. 
Two possible causes can explain the failure of foetal allele amplification: first, the 
excess of plasma DNA of maternal origin suppresses the primer binding to the 
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foetal plasma DNA, and second, the smaller length of the foetal plasma DNA 
reduces the probability of primer binding. Also sex marker Amelogenin failed the 
amplification in case of pregnant women carryng a male foetus, indicating that other 
specific Y chromosome markers are to be preferred, instead of the proposed 
Amelogenin, differing in female and male for 6 base pairs only. 
Our attempts to investigate foetal STR profiles from plasma DNA of pregnant 
women, carrying also a small proportion of free foetal DNA continued with, the 
recently introduced technology in molecular genetics, the next generation deep 
sequencing (NGS). 
NGS is a sequencing technology of recent introduction in molecular genetics. SNPs, 
repeat structure variations and low quantities of genomic material that go 
undetected on CE are recently discovered with NGG [7].  
Is has been demonstrated that pyrosequencing has a deep capacity of data 
generation and discriminatory power [8]. The peak information from CE results 
contains a value for the size of the peak, while the deep sequencing processed data 
gives the ratios of the various sequences and reveals base resolution information. 
We applied the single molecule sequencing, commonly referred to as Next 
Generation Sequencing on DNA a pregnant woman and her partner. We used a 
second-generation sequencing platform - Roche Genome Sequencer 454 Life 
Science Titanium - for four STR loci of forensic interest. 
We tested the capacity of data generation and discriminatory power to detect also 
sequences of foetal origin. Comparing the NGS data with the CE data we showed 
that foetal DNA alleles were present in mother’s to plasma. Unfortunately, 
Amelogenin of Y chromosome origin was not sequenced (being the foetus a male). 
For two autosomal allele we not only demostrated the foetal presence, but also the 
repeat structure variations corresponding to those of paternal origin. Imbalance of 
foetal and maternal allele ratio was detected, and more efforts have to be employed 
to understand this phenomenum. 
Even if further optimization of the multiplex amplification is necessary, we 
demonstrated for the first time that foetal STR profiles could be investigated with 
next generation sequencing on pregnant plasma DNA. 
The recovered data and resulting alligned reads were more than sufficient to reveal 
sequence variation among samples. The additional discriminatory power provided 
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by SNPs otherwise indiscernible and the possibility to multiplex many markers with 
overlapping size ranges highlight the benefits of foetal STR sequencing on the 454 
platform, opening the possibility to explore genetic features also for genetic prenatal 
non-invasive diagnosis. 
The family we explored with the 454 NGS was the one in which STR fingerprint on 
enriched erythroblast cells of presumptive foetal origin circulating on pregnant 
whole blood gave amplification of STR alleles different from the maternal ones and 
corresponding to those in the cord blood at delivery, also matching with those of the 
putative father. Anyway the sporadic amplification is not sufficient for reliable 
paternity testing.  
 
Finally, the results obtained in this research project, can be summarized as follows: 
- genetic non-invasive prenatal diagnosis present specific features that allow 
ethically feasible applications also for non medical purposes; 
- between non medical applications, NIPPT represents the more usefull methods, 
above all in forensic genetics, such as the investigation of perpetretors in case of 
rape-related pregnancy and paternity in case of suspect of erroneous embryo 
transfer; 
- free foetal DNA in pregnant plasma DNA represents a promising matrix if 
investigated with next generation sequencing, even if optimization of the multiplex 
amplification is necessary; 
- nucleated red blood cells, even are considered the more useful foetal cells  for non 
invasive prenatal diagnosis, are challenging in detection, and difficult to be explored 
by multiplex PCR. 
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